Chile News API

Supported Countries - 165

Afghanistan

Albania

Algeria

Angola

Argentina

Australia

Austria

Azerbaijan

Bahamas

Bahrain

Bangladesh

Barbados

Belarus

Belgium

Belize

Bermuda

Bhutan

Bolivia

Bosnia And Herzegovina

Botswana

Brazil

Brunei

Bulgaria

Cambodia

Cameroon

Canada

Cape Verde

Cayman Islands

Central African Republic

Chile

China

Colombia

Comoros

Congo

Costa Rica

Croatia

Cuba

Cyprus

Czech Republic

DR Congo

Denmark

Djibouti

Dominica

Dominican Republic

Ecuador

Egypt

El Salvador

Estonia

Ethiopia

Fiji

Finland

France

French Polynesia

Gabon

Georgia

Germany

Ghana

Greece

Guatemala

Guinea

Haiti

Honduras

Hong Kong

Hungary

Iceland

India

Indonesia

Iran

Iraq

Ireland

Israel

Italy

Ivory Coast

Jamaica

Japan

Jordan

Kazakhstan

Kenya

Kuwait

Kyrgyzstan

Laos

Latvia

Lebanon

Libya

Lithuania

Luxembourg

Macedonia

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Mauritania

Mauritius

Mexico

Moldova

Monaco

Mongolia

Montenegro

Morocco

Mozambique

Myanmar

Namibia

Nepal

Netherland

New Zealand

Niger

Nigeria

North Korea

Norway

Oman

Pakistan

Palestine

Panama

Papua New Guinea

Paraguay

Peru

Philippines

Poland

Portugal

Puerto Rico

Qatar

Romania

Russia

Rwanda

Samoa

Saudi Arabia

Senegal

Serbia

Singapore

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Korea

Spain

Sri Lanka

Sudan

Sweden

Switzerland

Syria

Taiwan

Tajikistan

Tanzania

Thailand

Tonga

Tunisia

Turkey

Turkmenistan

Uganda

Ukraine

United Arab Emirates

United Kingdom

United States Of America

Uruguay

Uzbekistan

Vanuatu

Venezuela

Vietnam

Yemen

Zambia

Zimbabwe

Get headlines from Chile with our JSON API.

🔑 Get API key for the Chile News API

Country Parameter

The country paramter for the Chile is CL.

Some example queries:

Below is the search query to fetch random 100 news-sources of Chile.

https://newsdata.io/api/1/sources?country=cl&apikey=YOUR_API_KEY

Some of the well known sources

Live Example

This example demonstrates the HTTP request to make, and the JSON response you will receive, when you use the News API to get headlines from Chile.

Headlines from Chile

https://newsdata.io/api/1/latest?country=cl&apikey=YOUR_API_KEY

{
  • "status": "success",
  • "totalResults": 3740,
  • -
    "results": [
    • -
      {},
    • -
      {},
    • -
      {},
    • -
      {
      • "article_id": "384d7b1d74e4ac9ab4cd62c736d68374",
      • "title": "Continúa el fuego cruzado entre India y Pakistán tras peores enfrentamientos en décadas",
      • "link": "https://www.latercera.com/mundo/noticia/continua-el-fuego-cruzado-entre-india-y-pakistan-tras-peores-enfrentamientos-en-decadas/",
      • "keywords": null,
      • "creator": null,
      • "description": "De acuerdo a los reportes, las hostilidades causaron al menos 44 muertos civiles, 31 del lado de Pakistán y 13 del lado indio.",
      • "content": "India y Pakistán continuaron el jueves intercambiando disparos de artillería en la frontera de la disputada región de Cachemira un día después de los peores enfrentamientos en dos décadas entre estas potencias atómicas vecinas.Según los últimos balances de ambas partes, las hostilidades causaron al menos 44 muertos civiles, 31 del lado de Pakistán y 13 del lado indio.El gobierno de Nueva Delhi también informó de un soldado fallecido por disparos pakistaníes.Los bombardeos indios sobre regiones fronterizas de Pakistán y el fuego cruzado entre ambos ejércitos en Cachemira representan una grave escalada en la crisis entre ambos países.Esta crisis comenzó el 22 de abril, con un atentado en la turística ciudad de Pahalgam, en la parte de Cachemira administrada por India, que mató a 26 personas, en su mayoría hindúes.La región de mayoría musulmana está dividida entre ambos países desde la independencia del Reino Unido en 1947, es escenario de una insurgencia de rebeldes que piden la independencia o la anexión a Pakistán.India, que acusa a Pakistán de respaldar estos grupos insurgentes, responsabilizó del ataque al país vecino y amenazó con una acción militar que se concretó el miércoles.Su ejército aseguró haber destruido nueve “campos terroristas” en Pakistán con “ataques aéreos de precisión” en Cachemira y la región fronteriza de Punyab, donde vive más de la mitad de los 240 millones de habitantes del país vecino.Poco después de esos bombardeos, los ejércitos de ambas naciones iniciaron un fuego cruzado a lo largo de la frontera en Cachemira que, según las fuerzas armadas indias, continuaron este jueves.“El ejército pakistaní efectuó disparos no provocados con armas pequeñas y artillería” a los que “el ejército indio respondió de forma proporcionada”, afirmó un comunicado militar de Nueva Delhi.“Vamos a vengar hasta la última gota de sangre de estos mártires”, prometió el miércoles por la noche el primer ministro pakistaní, Shehbaz Sharif.Sus fuerzas armadas reivindicaron en la víspera haber abatido cinco cazas de combate indios en la parte de Cachemira administrada por Nueva Delhi.Las autoridades indias no confirmaron oficialmente esas pérdidas, aunque una fuente de seguridad bajo anonimato confirmó a AFP que tres aviones militares se estrellaron en su territorio.El bombardeo más letal de la aviación india impactó un seminario islámico cerca de la ciudad de Bahawalpur, en el Punyab. Según el ejército pakistaní, 13 personas murieron en ese lugar.Llamados a la moderaciónHacía días que se esperaba una respuesta militar de India al ataque del 22 de abril, que no fue reivindicado pero que Nueva Delhi vincula al grupo yihadista Lashkar-e-Taiba (LeT), radicado en Pakistán.La organización, designada como terrorista por la ONU, es sospechosa de unos atentados en 2008 en Bombay que dejaron 166 muertos.India y Pakistán libraron múltiples guerras desde la partición e independencia de los dominios británicos en el subcontinente indio.“El mundo no puede permitirse una confrontación militar entre India y Pakistán”, alertó Stephane Dujarric, portavoz del secretario general de la ONU António Guterres.El secretario británico de Comercio, Jonathan Reynolds, ofreció la mediación de su país para apoyar un acercamiento entre ambos países.Estados Unidos, la UE, Rusia y Francia lanzaron también llamados a la moderación. “Quiero que se detengan” las hostilidades, declaró Donald Trump en la Casa Blanca.El conflicto no se limita al terreno militar. Horas antes de los bombardeos, Modi dijo que su administración iba a interrumpir el flujo de agua de sus ríos hacia Pakistán. Islamabad respondió que consideraría tal medida como “un acto de guerra”.",
      • "pubDate": "2025-05-08 09:14:52",
      • "pubDateTZ": "UTC",
      • "image_url": "https://www.latercera.com/resizer/v2/BV63PFCSAVEUNIL56BPBIZGVYA.jpg?auth=af28045c57a96b879bb711780410b0f8a1e999aca9e6727447bcb4a3f6785e75&height=1080&smart=true&width=1920",
      • "video_url": null,
      • "source_id": "latercera",
      • "source_name": "Latercera",
      • "source_priority": 42323,
      • "source_url": "https://www.latercera.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/latercera.jpg",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "sports",
        • "accidents"
        ],
      • -
        "ai_region": [
        • "pakistan,asia",
        • "india,asia"
        ],
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {},
    • -
      {},
    • -
      {},
    • -
      {},
    • -
      {},
    • -
      {
      • "article_id": "a33562321df952780f9d7e78a03da30a",
      • "title": "HORÓSCOPO DEL JUEVES 8 DE MAYO",
      • "link": "https://www.elrancaguino.cl/2025/05/08/horoscopo-del-jueves-8-de-mayo/",
      • -
        "keywords": [
        • "horóscopo",
        • "horoscopo"
        ],
      • -
        "creator": [
        • "Redacción El Rancagüino"
        ],
      • "description": "Por Ignacio Teodoro. ARIES (21 de marzo – 20 de abril).Los cambios climatológicos no deberían incrementar tu tendencia hacia una alimentación desordenada. La fruta, la verdura y en general las comidas no grasientas son fundamentales para tomar fuerzas y dar el empujón hacia las vacaciones. TAURO (21 abril – 20 mayo).Necesitas tomar decisiones sobre tu [...]El artículo HORÓSCOPO DEL JUEVES 8 DE MAYO se publicó primero en El Rancagüino.",
      • "content": "Por Ignacio Teodoro.ARIES (21 de marzo – 20 de abril).Los cambios climatológicos no deberían incrementar tu tendencia hacia una alimentación desordenada. La fruta, la verdura y en general las comidas no grasientas son fundamentales para tomar fuerzas y dar el empujón hacia las vacaciones.TAURO (21 abril – 20 mayo).Necesitas tomar decisiones sobre tu salud o tu imagen, y hoy será un buen día para ello, porque conocerás detalles e informaciones que completarán tus nociones sobre los temas que te interesan. No le des más vueltas.GÉMINIS (21 mayo – 21 junio).Hoy puede ser un buen día para tu crecimiento interior si consigues encauzar adecuadamente el lado positivo de las cosas. Tienes a favor, como tu inteligencia y la facilidad para gestionar tus recursos, pero debes de ser más optimista ante tus retos.CÁNCER (22 junio – 22 julio).Las cuestiones del trabajo serán agridulces para ti durante estos días, con logros importantes y también despistes notables, que te pueden acarrear algún problema. No te duermas en los laureles y céntrate en tus tareas.LEO (23 julio – 22 agosto).En ocasiones te muestras demasiado influenciable. Deberás hacer lo que te dicta tu buen juicio para solucionar tus problemas, sin atender a las opiniones de personas que en realidad no los conocen demasiado. De la familia sí vendrán buenos consejos.VIRGO (23 agosto – 21 septiembre).Necesitarás salir de compras en estos momentos, pero no para gastar mucho dinero, sino para ponerte al día de las nuevas tendencias que llegan; necesitas algo de aire fresco en tu estilo y en tu vestuario, y ahora es el momento de tomarlo.LIBRA (22 septiembre – 22 octubre).Las mejoras de suelto prometidas en el trabajo no terminan de llegar, y tendrás que reclamarlas de nuevo. Aunque es una situación conocida, mostrarás inseguridad. Trata de calmar tu impaciencia y todo se resolverá positivamente.ESCORPIO (23 octubre – 21 noviembre).Tendrás tiempo para pensar en tus nuevos proyectos personales y profesionales. Verás que es un momento ideal para crecer en el aspecto personal, no tanto en el del trabajo o los negocios, que deben quedar como están.SAGITARIO (22 noviembre – 22 diciembre).Haz un pequeño esfuerzo, y trata de mantener la serenidad en todo momento. Haz todo lo posible por dedicarte a los asuntos cotidianos de una manera sosegada y tranquila, sin dejar que nada ni nadie te agobie. Aprende a reírte de tus errores.CAPRICORNIO (23 diciembre – 21 enero).Amarás aún más tu independencia, sobre todo ante quien crees que tienes menos capacidades que tú. Tendrás que hacer un esfuerzo por reconocer la autoridad que da un puesto, aunque creas que el que lo posee no lo merece. Una fiesta aligerará tu mente.ACUARIO (22 enero – 21 febrero).Algunos amigos te han dado la espalda y sientes dolor y angustia, sin saber cómo subsanar el daño que has provocado. Trágate el orgullo, aunque no sea fácil, y reúnete con ellos para disculparte. No te queda otra.PISCIS (22 de febrero – 20 de marzo).Las relaciones personales más directas no serán lo tuyo en un día como el de hoy, en que habrás dejado lo bueno del fin de semana atrás para enfrentarte a las pequeñas miserias del día a día. Procura ponerte también en el lugar de los otros si debes exigirles algo.El artículo HORÓSCOPO DEL JUEVES 8 DE MAYO se publicó primero en El Rancagüino.",
      • "pubDate": "2025-05-08 08:18:08",
      • "pubDateTZ": "UTC",
      • "image_url": null,
      • "video_url": null,
      • "source_id": "elrancaguino_cl",
      • "source_name": "El Rancagüino",
      • "source_priority": 236223,
      • "source_url": "https://www.elrancaguino.cl",
      • "source_icon": "https://i.bytvi.com/domain_icons/elrancaguino_cl.jpg",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "awards and recognitions"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {},
    • -
      {
      • "article_id": "18f75c28c794f03c8fc48acc44ba1ebf",
      • "title": "El rediseño de imagen de marca y lo que dice sobre el presente corporativo",
      • "link": "https://www.elmostrador.cl/agenda-pais/2025/05/08/el-rediseno-de-imagen-de-marca-y-lo-que-dice-sobre-el-presente-corporativo/",
      • "keywords": null,
      • "creator": null,
      • "description": null,
      • "content": "En un mundo corporativo que se transforma a ritmo acelerado por la tecnología, los cambios sociales y las nuevas expectativas del mercado, no solo los productos y servicios necesitan adaptarse. También lo hacen las marcas, sus símbolos y la manera en que se presentan ante el mundo. El reciente rediseño de la identidad visual de PwC, una de las firmas globales más influyentes en consultoría y servicios profesionales, es un ejemplo más de cómo las empresas están replanteando su imagen para mantenerse en sintonía con los tiempos que corren. La renovación, anunciada este 29 de abril, es la primera en 14 años y se enmarca en la campaña “So You Can”, con una propuesta que busca reflejar una organización más conectada, innovadora y preparada para enfrentar las demandas de un entorno en constante evolución. El nuevo posicionamiento de marca incluye un logo actualizado con una nueva “marca de impulso”, un color naranja característico y una nueva imagen. Pero aunque incluye un nuevo logotipo, una marca de impulso y un tono visual revitalizado, el cambio va más allá de lo estético: representa un esfuerzo estratégico por alinearse con las nuevas dinámicas del mercado y con los valores que hoy exigen clientes, empleados y la sociedad en general. Este tipo de transformación no es nueva, pero ha cobrado más fuerza en los últimos años. Grandes marcas como Mastercard, Volvo, o incluso instituciones como el MIT, han actualizado su imagen para reflejar una mayor cercanía con lo digital, una postura más amigable y transparente, o una sensibilidad frente a desafíos como el cambio climático o la diversidad. En ese sentido, el rediseño de PwC responde a una lógica más profunda: el branding como herramienta de adaptación estratégica. Antonia Wade, Chief Marketing Officer global de la firma, explicó que esta evolución busca “proporcionar la plataforma adecuada para el futuro”, en un contexto donde la tecnología y otras megatendencias están transformando la economía. Por su parte, desde Chile, Joaquín Pérez, socio de Asuntos Corporativos de PwC, señaló que la nueva identidad posiciona de forma más clara las capacidades que la firma ofrece tanto a clientes como a nuevos talentos. Más que una operación de maquillaje, la actualización visual funciona como una declaración de principios. En un ecosistema saturado de mensajes, una identidad clara, coherente y actualizada puede marcar la diferencia entre conectar o perder relevancia. Además, en industrias basadas en la confianza —como la consultoría—, el lenguaje visual también transmite seriedad, modernidad y visión de futuro. PwC no está sola en este camino. El rediseño de imagen se ha convertido en una herramienta clave para comunicar transformación interna, crecimiento sostenible o cambio cultural. Las empresas, cada vez más, entienden que la marca no es solo un logotipo, sino la manifestación tangible de lo que son y aspiran a ser. Al renovar su imagen, PwC no solo busca verse distinta, sino también actuar en coherencia con un mundo donde, como ellos mismos señalan, “la reinvención es la única constante”. Y en ese espejo, muchas otras organizaciones también se miran.",
      • "pubDate": "2025-05-08 06:19:45",
      • "pubDateTZ": "UTC",
      • "image_url": "https://media-front.elmostrador.cl/2025/05/pexels-photo-5313161-700x403.jpeg",
      • "video_url": null,
      • "source_id": "elmostrador",
      • "source_name": "El Mostrador",
      • "source_priority": 239305,
      • "source_url": "https://www.elmostrador.cl",
      • "source_icon": "https://i.bytvi.com/domain_icons/elmostrador.png",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "entertainment"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {
      • "article_id": "72c3fd3137da7f2e1697a3bb3fb370d0",
      • "title": "Experiencias únicas en viñas para celebrar el Día de la Madre",
      • "link": "https://www.elmostrador.cl/revista-jengibre/gastronomia/2025/05/08/experiencias-unicas-en-vinas-para-celebrar-el-dia-de-la-madre/",
      • "keywords": null,
      • "creator": null,
      • "description": null,
      • "content": "Una botella de buen vino puede ser el inicio de una hermosa celebración, pero una experiencia enoturística va más allá: es una invitación a desconectarse de la rutina, a disfrutar del paisaje, a reencontrarse con la calma y a vivir momentos que se atesoran para siempre. Las viñas no solo guardan aromas y sabores únicos, también son escenarios perfectos para compartir, conversar y reconectar. Recorrer una bodega, participar en una cata guiada o simplemente disfrutar de un almuerzo entre viñedos es una forma distinta y especial de decirle a mamá cuánto la valoras. Porque ella merece lo mejor, este año sorpréndela con un regalo que celebra su historia, su entrega y su amor incondicional. ChezCarlita y La Academia del Vino realizarán un espectacular viaje de vinos al corazón del Valle de Almahue, visitando la histórica y encantadora Viña Clos de Luz. Este reconocido viñedo familiar, liderado por Gabriel Edwards, quinta generación de productores, es famoso por custodiar las parras de Carménère más antiguas de Chile y elaborar vinos que combinan magistralmente tradición y modernidad. Habrá un menú chileno preparado especialmente para esta ocasión, maridado cuidadosamente con vinos seleccionados. Otra alternativa es la que ofrece VSPT Wine Group. Para quienes prefieren salir de la ciudad, Viñamar, San Pedro y Tarapacá ofrecen experiencias enogastronómicas. Desde tour gratuitos para mamás en Casablanca, hasta almuerzos maridados en Cachapoal y menús de autor en Maipo, estas viñas combinan naturaleza, historia y vinos premium para una jornada especial En el marco del Día de la Madre Enoturismo Chile de Corfo presenta una guía exclusiva y gratuita con más de 20 experiencias enológicas y turísticas para sorprender a las mamás con regalos memorables. Desde catas premium entre viñedos centenarios hasta almuerzos gourmet con vistas a la cordillera, esta iniciativa busca promover la oferta de las viñas chilenas y ofrecer alternativas diferentes para celebrar en familia. La guía incluye actividades con descuentos especiales, como el Tour Emblema de Viña Maquis, el Brindis por Mamá de Viña Casa Silva (con degustación de vinos reserva y copa de obsequio), o el Yoga & Wine en Kingston Family Vineyards. Además, destacan experiencias novedosas como el Tour Astronómico Ancestral en Viña Santa Cruz y talleres para crear ensamblajes personalizados en Viña Ranquilhue. Muchas de estas opciones incluyen beneficios exclusivos, como 2×1, 50% de descuento para mamás o códigos promocionales. Esta campaña no solo busca fomentar el turismo en las viñas, sino también revalorizar el tiempo en familia y el contacto con la naturaleza. Muchas de las experiencias propuestas —como los picnics entre parras o los recorridos por viñedos agroecológicos— están diseñadas para crear conexiones auténticas, lejos de lo convencional. La iniciativa también apunta a reactivar la economía de los valles vitivinícolas, apoyando a viñas boutique y productores locales que ofrecen actividades con identidad territorial. “Quisimos reunir lo mejor del enoturismo nacional en una sola guía, para que el público encuentre ideas únicas y cercanas. El objetivo es potenciar las viñas como destinos turísticos en fechas clave y demostrar que el vino no solo se disfruta en copas, sino también a través de experiencias sensoriales, culturales y gastronómicas”, explica Alicia Ortiz, Gerente de Enoturismo Chile. La guía está disponible para descarga gratuita en enoturismochile.cl/descargas , con información detallada sobre horarios, precios, ubicaciones y contactos para reservas. Las actividades se extienden a lo largo de todo el país y muchas son válidas durante todo el mes de mayo.",
      • "pubDate": "2025-05-08 05:59:41",
      • "pubDateTZ": "UTC",
      • "image_url": "https://media-front.elmostrador.cl/2020/05/enoturismo-700x448.jpg",
      • "video_url": null,
      • "source_id": "elmostrador",
      • "source_name": "El Mostrador",
      • "source_priority": 239305,
      • "source_url": "https://www.elmostrador.cl",
      • "source_icon": "https://i.bytvi.com/domain_icons/elmostrador.png",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "awards and recognitions"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {},
    • -
      {
      • "article_id": "575844ef021097047025eae07bd53fb3",
      • "title": "Cáncer de ovario en Chile: síntomas, detección temprana y nuevas tecnologías para su diagnóstico",
      • "link": "https://www.elmostrador.cl/braga/2025/05/08/cancer-de-ovario-en-chile-sintomas-deteccion-temprana-y-nuevas-tecnologias-para-su-diagnostico/",
      • "keywords": null,
      • "creator": null,
      • "description": null,
      • "content": "Este 8 de mayo se conmemora el Día Mundial del Cáncer de Ovario , por lo que es necesario desterrar mitos que retrasan el diagnóstico y difundir los avances de la medicina nuclear, que hoy permite cambiar el pronóstico de las pacientes. El cáncer de ovario es una patología que afecta principalmente a las células de uno o ambos ovarios, en donde ocurre un crecimiento anormal de células produciendo tumores maligno s. Según la Fundación Arturo López Pérez e International Agency for Research on Cancer (Globocan), para el 2020 en Chile se estaban diagnosticando al año más de 800 casos nuevos de esta enfermedad, de las cuales alrededor de 500 personas fallecieron. Es fundamental, para prevenir y detectar tempranamente cualquier enfermedad que las personas acudan a controles de salud de manera anual . Es complejo hablar de autocuidado en contextos precarizados, pero es una responsabilidad social incentivar y promover la salud desde los diferentes espacios. En ese sentido, para el caso específico de las enfermedades en el sistema reproductor, es crucial asistir a la ginecóloga/o y/o matrón/a para realizar una ecografía y exámenes físicos. “Si bien ninguno de estos exámenes son diagnósticos para el cáncer de ovario, pueden ser utilizados para observar cualquier cambio importante en la historia de la persona”, aseveran desde APROFA, agregando que “estos se deben realizar al menos una vez al año, en conjunto con todo el control ginecológico”. Según las profesionales del Área de Salud de APROFA, la mayoría de las personas que tienen cáncer de ovario son asintomáticas, es por ello que el 75% de este tipo de cáncer es diagnosticado en etapa avanzada . “Para el caso de aquellas personas que sí presentan síntomas, estos pueden ser dolor abdominal o pélvico, aumento del volumen abdominal, urgencia urinaria, dificultad para comer, saciedad precoz, baja de peso, dolor lumbar y falta de energía . Sin embargo, todos estos síntomas son bastante inespecíficos como para determinar una sospecha, además de que cada persona puede presentar diferentes señales ”, detallan. Horacio Amaral, director médico de PositronMed, explica que la detección temprana es la mejor herramienta para salvar vidas. “Las tecnologías PET CT de última generación permiten evaluar extensión tumoral con una sensibilidad inédita y planificar tratamientos más precisos”, destaca. Solo afecta a mujeres mayores : Aunque el riesgo aumenta con la edad, puede presentarse también en mujeres jóvenes; entonces, ante los síntomas persistentes, se requiere una evaluación sin importar la edad. “Si hay antecedentes familiares previos, es importante realizar un chequeo médico anual para descartar la presencia de tumores”, explica el Dr. Amaral. La quimioterapia es la única opción : Hay otros tratamientos disponibles como la cirugía citorreductora, quimioterapia dirigida, terapias anti‐angiogénicas, inhibidores de PARP y radioterapia metabólica. Todas estas forman un arsenal terapéutico combinado, que mejora sustancialmente la recuperación de las pacientes. Los últimos radiofármacos permiten generar mapas tumorales de alta resolución para detectar implantes peritoneales de apenas unos milímetros con mayor contraste que los radiofármacos clásicos y permite cuantificar la respuesta al tratamiento casi en tiempo real. Esta precisión mejora la estadificación antes y después de la quimioterapia neoadyuvante y según estudios recientes, alcanza una sensibilidad superior al 90 % en cáncer de ovario, cambiando la estrategia terapéutica en cerca de un tercio de las pacientes. “La tecnología PET-CT nos permite identificar lesiones mínimas y ajustamos las terapias dirigidas con rapidez, lo que no sólo incrementa la supervivencia; también evita cirugías innecesarias y reduce la toxicidad ”, finaliza Amaral. El llamado es que todas las mujeres conozcan sus factores de riesgo, escuchar su cuerpo y consultar de inmediato ante síntomas persistentes. Detectar a tiempo salva vidas, por lo que se debe consultar con un ginecólogo sobre las opciones de diagnósticos avanzados , incluido el PET‐CT con radiofármacos de última generación disponibles en Chile. Más información sobre los servicios de PositronMed y recomendaciones adicionales sobre la medicina nuclear, están disponibles en el sitio web oficial www.positronmed.cl o en el Instagram oficial @positronmed.cl.",
      • "pubDate": "2025-05-08 05:44:30",
      • "pubDateTZ": "UTC",
      • "image_url": "https://media-front.elmostrador.cl/2025/05/Cancer-de-ovario-en-Chile.jpeg",
      • "video_url": null,
      • "source_id": "elmostrador",
      • "source_name": "El Mostrador",
      • "source_priority": 239305,
      • "source_url": "https://www.elmostrador.cl",
      • "source_icon": "https://i.bytvi.com/domain_icons/elmostrador.png",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "awards and recognitions"
        ],
      • -
        "ai_region": [
        • "chile,south america"
        ],
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {},
    • -
      {},
    • -
      {
      • "article_id": "d5160690aaad71a33e3c210d9dab915e",
      • "title": "Ataque incendiario destruye cinco vehículos y maquinaria en predio forestal en Los Sauces",
      • "link": "https://www.latercera.com/nacional/noticia/ataque-incendiario-destruye-cinco-vehiculos-y-maquinaria-en-predio-forestal-en-los-sauces/",
      • "keywords": null,
      • "creator": null,
      • "description": "Desde la Seremi de Seguridad Pública señalaron que se encontraron consignas relativas a la causa mapuche, aunque ninguna organización se ha adjudicado el hecho.",
      • "content": "Un nuevo atentado incendiario se registró la noche de este miércoles en un predio forestal resultaron destruidos en la comuna de Los Sauces, en la Región de La Araucanía.En específico, el ataque habría sido perpetrado por tres sujetos encapuchados que llegaron hasta el fundo Nabañir, que es propiedad de la empresa CMPC, donde prendieron fuego a cinco camionetas y tres máquinas usadas para labores forestales.La seremi de Seguridad Pública, Verónica López-Videla, aseguró que los desconocidos “intimidaron a los trabajadores del lugar, encerrándolos en un módulo de comedor” tras lo cual incendiaron los vehículos.Asimismo, López-Videla señaló que “se encontraron algunos rayados alusivos a la libertad de presos políticos mapuche. Sin embargo, hasta el momento no se han encontrado ni lienzos ni pancartas donde algún grupo se adjudique este atentado”.El subprefecto de Carabineros de la Prefectura de Malleco, Raúl Quintanilla, señaló que hasta el lugar se debió trasladar personal de Control de Orden Público (COP) para resguardar el sitio del suceso, además de informar que no hubo personas lesionadas.Ante lo anterior, el diputado Jorge Rathgeb (RN), emplazó a las distintas autoridades encargadas de la seguridad. “El gobierno se descuidó con nuestra región y está retornando la violencia. Presidente Boric, ministro Cordero, ministro Elizalde, ministra Delpiano, vengan a La Araucanía”, señaló a través de su cuenta en X.Su correligionaria, la senadora María José Gatica, en tanto, afirmó que “el gobierno por un lado arma una comisión para la paz y el entendimiento y por otra, en la Cámara de Diputados, le quita la urgencia a la RUF. Resumen solo les interesa el discurso, pero no combatir el terrorismo y la guinda de la torta, nuevo atentado en Los Sauces”.Desde la Asociación para la Paz y la Reconciliación en La Araucanía (APRA) afirmaron que “el atentado destruyó por completo maquinaria pesada y camionetas pertenecientes a la empresa EESS Cima, que presta servicios a CMPC\".“Afortunadamente, no se reportan heridos, pero los trabajadores quedaron profundamente impactados y con temor tras el violento hecho. El terrorismo vuelve a golpear a La Araucanía, arrasando con el esfuerzo de quienes se ganan la vida con trabajo honesto. El Estado debe reaccionar. No podemos seguir aceptando esta barbarie como si fuera parte de la rutina”, sostuvo la organización.",
      • "pubDate": "2025-05-08 05:36:24",
      • "pubDateTZ": "UTC",
      • "image_url": "https://www.latercera.com/resizer/v2/UH6PK67YIJBW7C6GDXBSFFGZFM.png?auth=d7684d2ee46be1296c26f9b1c022decfba08ea831eea9d14d46e4d9a7001d93b&height=622&smart=true&width=1106",
      • "video_url": null,
      • "source_id": "latercera",
      • "source_name": "Latercera",
      • "source_priority": 42323,
      • "source_url": "https://www.latercera.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/latercera.jpg",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "awards and recognitions"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {
      • "article_id": "84d0eaaa1aaa21c1c50693b1171836f1",
      • "title": "Fiscalización en carretera deja 4 extranjeros detenidos y casi un millón de dosis de droga incautada",
      • "link": "https://www.portalnet.cl/temas/fiscalizacion-en-carretera-deja-4-extranjeros-detenidos-y-casi-un-millon-de-dosis-de-droga-incautada.1557738/",
      • "keywords": null,
      • -
        "creator": [
        • "invalid@example.com (Centurion_cl)",
        • "Centurion_cl"
        ],
      • "description": null,
      • "content": "Fiscalización en carretera deja cuatro extranjeros detenidos y casi un millón de dosis de droga incautadas en Antofagasta En menos de una semana, la Carabineros ha decomisado más de 2 toneladas de sustancias ilícitas en la región. En lo que va del año, la cifra total supera las 10 toneladas. (Foto: PDI Antofagasta/ Fiscalía Antofagasta) Un control vehicular realizado por Carabineros en Calama permitió interceptar un cargamento de casi 470 kilos de marihuana que iba con destino a la zona central del país. La fiscalización terminó con dos ciudadanos bolivianos detenidos y fue el inicio de una investigación que derivó en un allanamiento, la captura de otros dos imputados —de nacionalidad colombiana — y la incautación de otros 24 kilos de droga. Todos los detenidos se encuentran en prisión preventiva tras ser formalizados por la Fiscalía, que detalló que los cuatro sujetos se encontraban en situación migratoria irregular y que el inmueble intervenido era utilizado como punto de acopio para la distribución de drogas hacia el centro del país. El fiscal regional, Juan Castro Bekios, advirtió que la región enfrenta un momento crítico en materia de tráfico de drogas, aunque valoró la efectividad de los operativos. “Solo en lo que va de este año ya tenemos 10,5 toneladas de drogas incautadas, lo que representa un 85% de incremento en relación a la misma fecha de 2024. Llama la atención el aumento de aproximadamente 440% de las incautaciones de cocaína y más de 2.000% en fármacos”, detalló. El seremi (s) de Seguridad Pública, Ignacio Rivera Muñoz, llamó a fortalecer las denuncias ciudadanas mediante el sistema *4242, recordando que el 80% de los reportes ingresados a través de esa vía están vinculados a delitos contemplados en la Ley 20.000. “Solo en la provincia de El Loa se concentra el 60% del total incautado en la región”, precisó. Finalmente, el general Cristian Montre, jefe de la Zona de Carabineros Antofagasta, señaló que los resultados responden a una estrategia operativa aplicada desde fines de 2023, con acciones integradas en zonas urbanas, rutas e investigaciones. “En las últimas cuatro semanas hemos incautado más de 4 toneladas y, en lo que va del año, nos acercamos a las 10 toneladas. Estas cifras históricas demuestran el impacto del trabajo preventivo y coordinado”, afirmó. Fuente: https://www.soychile.cl/antofagasta/policial/2025/05/02/904458/incautacion-droga-antofagasta.html Sitio:Soychile.cl",
      • "pubDate": "2025-05-08 05:15:11",
      • "pubDateTZ": "UTC",
      • "image_url": "https://i.postimg.cc/pLH6QYx3/file-20250502162217.jpg",
      • "video_url": null,
      • "source_id": "portalnet_cl",
      • "source_name": "Portalnet.cl",
      • "source_priority": 53687,
      • "source_url": "https://www.portalnet.cl",
      • "source_icon": "https://i.bytvi.com/domain_icons/portalnet_cl.jpg",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "world"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "sports",
        • "awards and recognitions"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {},
    • -
      {
      • "article_id": "831111e2fc5b8434a270f7de4d6d75ce",
      • "title": "Peligrosa persecución en Nacimiento termina con un extranjero detenido y droga incautada",
      • "link": "https://www.portalnet.cl/temas/peligrosa-persecucion-en-nacimiento-termina-con-un-extranjero-detenido-y-droga-incautada.1557736/",
      • "keywords": null,
      • -
        "creator": [
        • "invalid@example.com (Centurion_cl)",
        • "Centurion_cl"
        ],
      • "description": null,
      • "content": "Peligrosa persecución en Nacimiento termina con un extranjero detenido y droga incautada Contexto | Carabineros de Nacimiento Durante la mañana de este miércoles, una persecución se prolongó por varias cuadras en la comuna de Nacimiento, logrando la detección de un extranjero que se encontraba comercializando sustancias ilícitas en un vehículo. Todo ocurrió cerca de las 10:30 horas, cuando personal de Carabineros de la Sección de Investigación Policial, SIP, de la Tercera Comisaría se encontraba realizando patrullajes preventivos. En ese momento, se percataron en la intersección de calles Pedro Aguirre Cerda con Mauricio Gleissner de un vehículo sospechoso con una persona en el interior. Ante esto, se le hicieron señales para que detuviera su marcha con la finalidad de realizar un control preventivo. Pero al ver la presencia de los efectivos, este procedió a darse a la fuga. Ahí, se comenzó a hacer un seguimiento a distancia, pero el individuo aumentó la velocidad. Ccomenzando así una peligrosa persecución por diferentes calles y pasajes de Nacimiento, siendo desplegados otras unidades. Droga encontrada en Nacimiento En un punto, por calle Arturo Alessandri, el antisocial arrojó por la ventana una bolsa transparente con una sustancia de color blanco, la cual fue recuperada. Posteriormente, se pudo interceptar el móvil y reducir a su conductor, para ser detenido. Confirmando que se trataba de un sujeto que fue identificado como T.M.A., de 37 años de edad y de nacionalidad dominicana. Siendo trasladado hasta la unidad para seguir con el procedimiento correspondiente. En relación a la bolsa, se pudo confirmar que se trataba de clorhidrato de cocaína, la cual estaba lista para ser dosificada y vendida en el comercio ilegal. Además, se incautó dinero en efectivo, el cual había sido originado por la venta de esta sustancia ilícita en diferentes sectores de Nacimiento. Finalmente, el Fiscal de Flagrancia del Ministerio Público fue informado de los hechos. Instruyendo que el detenido pasara a control de detención ante el tribunal competente durante la presente jornada. Además, se dispuso el envío de la sustancia incautada al Servicio de Salud para su análisis correspondiente y cadena de custodia. https://elcontraste.cl/policial/202...con-un-extranjero-detenido-y-droga-incautada/",
      • "pubDate": "2025-05-08 05:08:24",
      • "pubDateTZ": "UTC",
      • "image_url": "https://elcontraste.cl/wp-content/uploads/2025/05/WhatsApp-Image-2025-05-07-at-8.05.17-PM-696x391.jpeg",
      • "video_url": null,
      • "source_id": "portalnet_cl",
      • "source_name": "Portalnet.cl",
      • "source_priority": 53687,
      • "source_url": "https://www.portalnet.cl",
      • "source_icon": "https://i.bytvi.com/domain_icons/portalnet_cl.jpg",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "world"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "entertainment"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {
      • "article_id": "5566232e92c1487566e3f1957064c5aa",
      • "title": "Cómo se destinarán los hasta US$ 4.000 millones para comunidades indígenas que demandan tierras",
      • "link": "https://www.portalnet.cl/temas/como-se-destinaran-los-hasta-us-4-000-millones-para-comunidades-indigenas-que-demandan-tierras.1557735/",
      • "keywords": null,
      • -
        "creator": [
        • "invalid@example.com (Centurion_cl)",
        • "Centurion_cl"
        ],
      • "description": null,
      • "content": "Cómo se destinarán los hasta US$ 4.000 millones para comunidades indígenas que demandan tierras El informe definió cuatro categorías para destinar hasta US$ 4.000 millones. Un 81,7% de los recursos serán para los casos de mayor consenso: comunidades con títulos reconocidos por Conadi, con solicitudes previas. Un 3,2% (hasta US$ 129 millones) serán para los más difíciles: comunidades sin títulos, pero con “vinculación territorial”. Por qué importa . El informe final de la Comisión Presidencial para la Paz y el Entendimiento detalló cómo distribuir los hasta US$ 4.000 millones que el documento propone repartir a comunidades indígenas con reclamaciones territoriales. Se trata de una fórmula que busca, por una parte, zanjar las demandas históricas originadas en el proceso conocido como la pacificación de La Araucanía del siglo XIX y que, con las condiciones actuales y sin ingreso de nuevas solicitudes de tierra, podría tardar “162 años”, dijo el informe. La propuesta busca, por otra parte, acotar los montos que el Estado destine a este propósito. Esto último deriva de que, según consigna el informe, la ley indígena permite que las demandas territoriales puedan “crecer indefinidamente”. La razón es “la posibilidad continua e ilimitada de constituir nuevas comunidades indígenas a partir del uso reiterado de Títulos de Merced (TM), ya que no existe un límite administrativo sobre cuántas veces puede utilizarse un mismo TM para este fin. Por otra parte, cada comunidad puede actualizar la cantidad de familias asociadas cada seis años, sin restricciones más allá de demostrar vínculos familiares”, detalló el documento. El informe fue entregado esta semana al Presidente Gabriel Boric sin alcanzar la unanimidad que se había autoimpuesto la instancia, luego de que el comisionado Sebastián Naveillán, representante de los agricultores de Malleco, rehusara firmar el acuerdo. La senadora Carmen Gloria Aravena apoyó el resultado tras renunciar al Partido Republicano, que se oponía. Las categorías . El informe definió cuatro categorías para destinar hasta US$ 4.000 millones. El mayor monto (US$ 3.266 millones, un 81,7% del total) se entregaría para los casos de mayor consenso: comunidades con títulos reconocidos por la Corporación Nacional de Desarrollo Indígena (Conadi), que habían hecho solicitudes previo a esta semana, en que la comisión entregó su propuesta. El segundo y tercer grupo (US$ 605 millones, un 15,1%) se destinaría tanto a comunidades constituidas previamente como no constituidas previamente pero que en ambos casos tengan demandas con títulos reconocidos. El cuarto grupo (US$129 millones, un 3,2%) son las comunidades constituidas previamente, pero que carezcan de títulos reconocidos por el estado chileno. El caso más complejo . “El Grupo 4 comprende a comunidades indígenas ya constituidas que, si bien no cuentan con una titulación histórica reconocida por el sistema vigente, presentan una vinculación territorial que ha sido invisibilizada o desdibujada por procesos históricos de despojo y colonización”, dijo el documento. “El mayor desafío”. “Este grupo plantea el mayor desafío para la política pública, ya que requiere desarrollar mecanismos especiales de análisis histórico, probatorio y territorial que vayan más allá de los registros actualmente disponibles”. Criterios de selección . “Se propone una delimitación clara del Grupo 4 a partir de tres criterios simultáneos”: Primero, “comunidades indígenas ya existentes al momento de las recomendaciones, lo que evita expandir el universo a futuros casos o solicitudes que puedan surgir posteriormente”. Segundo, “estas comunidades deben ubicarse exclusivamente en las provincias de Arauco y Malleco, territorios donde la baja presencia de títulos indígenas no responde a una ausencia del pueblo Mapuche, sino a procesos de colonización temprana que excluyeron estos territorios del reparto formal mediante títulos”. Esta colonización temprana por civiles derivó en adquisiciones que no dejaron mayores registros. Tercero, “se considerarán únicamente aquellas comunas cuya superficie reconocida mediante Títulos de Merced u otros instrumentos reconocidos actualmente por Conadi represente menos del 4% de la superficie comunal total”. Las seis comunas. “Existen seis comunas en las provincias de Arauco y Malleco con titulación menor al 4% (Arauco, Curanilahue, Lebu, Los Álamos, Angol y Curacautín), que implicarían una demanda máxima no titulada del Grupo 4 de 14.914 hectáreas”. Monto máximo. “Si se establece, además, un límite máximo de 5% de aumento de familias en las comunidades involucradas a esa demanda. El total de la demanda del Grupo 4 ascendería como máximo a USD$ 129 millones”. Monto podría ser menor . “Cabe destacar que este fondo es una cota máxima, pues puede que varias de estas comunidades postulen al sistema en el marco de los Grupos 1 y 2, los cuales son más sencillos”. Panorama general . “Entre 1993, año en que se promulgó la Ley Indígena, y 2024, la Conadi ha llevado a cabo un proceso de reparación territorial mediante la adquisición de tierras indígenas, logrando un total de 230.563 hectáreas adquiridas durante ese período en las cuatro regiones” estudiadas. Estas son el Biobío, La Araucanía, Los Ríos y Los Lagos. https://www.ex-ante.cl/como-se-prop...s-comunidades-indigenas-que-demandan-tierras/ Se viene un choreo gigantesco...",
      • "pubDate": "2025-05-08 05:05:13",
      • "pubDateTZ": "UTC",
      • "image_url": "https://www.ex-ante.cl/wp-content/uploads/2025/05/Boric-2-768x432.png",
      • "video_url": null,
      • "source_id": "portalnet_cl",
      • "source_name": "Portalnet.cl",
      • "source_priority": 53687,
      • "source_url": "https://www.portalnet.cl",
      • "source_icon": "https://i.bytvi.com/domain_icons/portalnet_cl.jpg",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "politics"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "financial markets"
        ],
      • -
        "ai_region": [
        • "united states of america,north america"
        ],
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {
      • "article_id": "e5ea3ba733b426154e61866cc9cf870f",
      • "title": "2400 afectados por cierre de PacificBlu tras fraccionamiento: acusa a subsecretario Pesca de mentir",
      • "link": "https://www.portalnet.cl/temas/2400-afectados-por-cierre-de-pacificblu-tras-fraccionamiento-acusa-a-subsecretario-pesca-de-mentir.1557734/",
      • "keywords": null,
      • -
        "creator": [
        • "invalid@example.com (Centurion_cl)",
        • "Centurion_cl"
        ],
      • "description": null,
      • "content": "2400 afectados por cierre de PacificBlu tras fraccionamiento: acusa a subsecretario de Pesca de mentir La empresa pesquera PacificBlu anunció la tarde de este miércoles el cierre de sus operaciones tras la aprobación de la reducción del fraccionamiento industrial en la pesquería de la merluza común de un 60% a un 48%. La decisión fue dada a conocer a través de un comunicado y se hará efectiva a partir del 1 de enero de 2026, una vez que comience a regir el nuevo fraccionamiento, tal y como señala el proyecto de ley. El fraccionamiento de la merluza común, de acuerdo al gerente general de la empresa , Marcel Moenne, “hace inviable la continuidad de nuestras operaciones en las condiciones actuales, un hecho que advertimos formalmente al Gobierno en reiteradas ocasiones y de manera pública con argumentos técnicos, económicos y sociales fundados”. Con el cierre de PacificBlu, más de 800 trabajadores se verán afectados de manera directa y otros 2.400 de manera indirecta. Moenne, además, acusó al subsecretario de Pesca, Julio Salas, de sustentarse “en datos falsos y no rigurosos, generando confusión en el debate parlamentario” del fraccionamiento de la merluza común. “El subsecretario, durante la sesión, mostró cifras de desembarque que señalaban que la industria logró capturar en 2024 solo el 61% de las cuotas cuando el dato real es de un 93%. Con esta información errónea argumentó que una baja en el fraccionamiento industrial no generaría falta de cuota para la operación de la compañía ni afectaría el empleo, lo que no es efectivo, ya que históricamente hemos capturado el 99% de nuestras cuotas”, explicó. Desde PacificBlu zanjan que la medida de fraccionamiento “destruirá una empresa: el país pierde capacidad industrial, empleo formal y desarrollo regional sostenible“. https://www.biobiochile.cl/noticias...aprobacion-de-fraccionamiento-a-merluza.shtml",
      • "pubDate": "2025-05-08 05:01:44",
      • "pubDateTZ": "UTC",
      • "image_url": "https://i.postimg.cc/rFbHdXYy/social-digital-10-1200x633.png",
      • "video_url": null,
      • "source_id": "portalnet_cl",
      • "source_name": "Portalnet.cl",
      • "source_priority": 53687,
      • "source_url": "https://www.portalnet.cl",
      • "source_icon": "https://i.bytvi.com/domain_icons/portalnet_cl.jpg",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "politics"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "accidents"
        ],
      • -
        "ai_region": [
        • "pacific,washington,united states of america,north america",
        • "pacific,missouri,united states of america,north america"
        ],
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {},
    • -
      {
      • "article_id": "8d68c56c7d9441181c416a27b9bb7d39",
      • "title": "Paro indefinido de Profesores de Coquimbo y Andacollo",
      • "link": "https://www.elregional.cl/?p=5698",
      • -
        "keywords": [
        • "regionales"
        ],
      • -
        "creator": [
        • ". ."
        ],
      • "description": "El Colegio de Profesores de Coquimbo anunció una paralización indefinida desde este miércoles 7 de mayo en los establecimientos del Servicio Local de Educación Pública (SLEP) Puerto Cordillera, que abarca las comunas de Coquimbo y Andacollo. La medida se debe, según el gremio, a «persistentes incumplimientos» del SLEP. Sin embargo, hay controversia en torno ...",
      • "content": "El Colegio de Profesores de Coquimbo anunció una paralización indefinida desde este miércoles 7 de mayo en los establecimientos del Servicio Local de Educación Pública (SLEP) Puerto Cordillera, que abarca las comunas de Coquimbo y Andacollo. La medida se debe, según el gremio, a «persistentes incumplimientos» del SLEP. Sin embargo, hay controversia en torno a la votación que definió el paro: de 38 colegios, solo 16 votaron a favor y 8 en contra. El resto no votó y, según el gremio, sus votos se sumaron a la mayoría. Pero desde algunos establecimientos aseguran que sus posturas en contra no fueron consideradas. Medios de prensa locales accedieron a resultados que indicarían que en realidad ganó la opción de no paralizar (20 contra 17), información que habría sido desestimada por el Colegio de Profesores. Pese a todo, el SLEP Puerto Cordillera informó que los colegios de Coquimbo estarán abiertos en horario normal, con clases, alimentación y transporte funcionando. En Andacollo y jardines infantiles, el servicio educativo continuará con normalidad. El SLEP lamentó la decisión del gremio, destacando avances en pagos, infraestructura y acuerdos para recuperación de clases.",
      • "pubDate": "2025-05-08 04:57:20",
      • "pubDateTZ": "UTC",
      • "image_url": "https://www.elregional.cl/wp-content/uploads/2025/05/3-2-780x470.jpg",
      • "video_url": null,
      • "source_id": "elregional",
      • "source_name": "Elregional",
      • "source_priority": 591489171,
      • "source_url": "https://www.elregional.cl",
      • "source_icon": "https://i.bytvi.com/domain_icons/elregional.png",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "awards and recognitions"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {},
    • -
      {
      • "article_id": "04be1516663eba1afa7e3bc4b35e31a3",
      • "title": "Humo negro en el cónclave: No hay acuerdo y la elección del Papa se pospone",
      • "link": "https://www.elregional.cl/?p=5694",
      • -
        "keywords": [
        • "mundo"
        ],
      • -
        "creator": [
        • ". ."
        ],
      • "description": "Este miércoles comenzó el esperado cónclave para elegir al próximo Papa, tras la muerte de Francisco. A las 16:00 horas, los 133 cardenales se congregaron en la capilla Sixtina, enfundados en sus hábitos rojos y blancos, para iniciar el solemne proceso. Con solemne recogimiento, los cardenales procesionaron hacia la capilla Sixtina mientras entonaban las letanías y el himno Vieni ...",
      • "content": "Este miércoles comenzó el esperado cónclave para elegir al próximo Papa , tras la muerte de Francisco. A las 16:00 horas, los 133 cardenales se congregaron en la capilla Sixtina, enfundados en sus hábitos rojos y blancos, para iniciar el solemne proceso. Con solemne recogimiento, los cardenales procesionaron hacia la capilla Sixtina mientras entonaban las letanías y el himno Vieni Creator . Luego, uno a uno, prestaron juramento bajo la solemne mirada del Evangelio, comprometiéndose al estricto silencio que caracteriza el cónclave. El juramento del silencio, que en caso de incumplirse implica una severa excomunión, es uno de los momentos más trascendentales de este proceso. El “Extra Omnes” y la Suspensa Expectativa Una vez realizado el juramento, llegó el momento de cerrar las puertas del recinto. Con la fórmula “Extra omnes” (Fuera todos), el maestro ceremoniero de la Santa Sede, Diego Ravelli, expulsó a todo el personal ajeno al grupo de cardenales. A partir de ese momento, el único sonido que se escucha es el de los participantes, sumidos en la estricta privacidad de la capilla Sixtina, mientras esperan la decisión que definirá al nuevo líder de la Iglesia Católica. El proceso, sin embargo, no es inmediato. Durante el día, se llevará a cabo una catequesis dirigida por el cardenal Raniero Cantalamessa, destinada a inspirar a los votantes antes de comenzar las votaciones. Tras esta, el momento más esperado se acercará: la fumata. La Espera Continúa: Humo Negro en la Primera Fumata La primera fumata del cónclave se espera alrededor de las 19:00 horas. Sin embargo, si el humo que asciende desde la capilla Sixtina es de color negro , eso significará que no ha habido acuerdo entre los cardenales , y la espera continuará por más días. Si el humo es blanco, la Iglesia ya tendrá un nuevo Papa. La elección no es sencilla. Para que un candidato sea elegido, se necesita una mayoría de dos tercios de los votos, un número que se redondea hacia arriba si la votación tiene decimales. Si no hay consenso en la primera ronda, se continuará con más votaciones, con nuevas fumatas previstas para la mañana y la tarde del día siguiente.",
      • "pubDate": "2025-05-08 04:50:08",
      • "pubDateTZ": "UTC",
      • "image_url": "https://www.elregional.cl/wp-content/uploads/2025/05/humo-negro-en-el-vaticano_610a2128_78897_250507220154_1280x853-780x470.webp",
      • "video_url": null,
      • "source_id": "elregional",
      • "source_name": "Elregional",
      • "source_priority": 591489171,
      • "source_url": "https://www.elregional.cl",
      • "source_icon": "https://i.bytvi.com/domain_icons/elregional.png",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "awards and recognitions"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {
      • "article_id": "fe5ee28487970dd3ef0accc78cfae7b6",
      • "title": "Zelensky wants to postpone election once more",
      • "link": "https://menafn.com/1109522709/Zelensky-wants-to-postpone-election-once-more",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN) Ukrainian President Volodymyr Zelensky has proposed a bill to extend martial law by another 90 days, effectively preventing the possibility of holding a presidential election during that ...",
      • "content": "( MENAFN ) Ukrainian President Volodymyr Zelensky has proposed a bill to extend martial law by another 90 days, effectively preventing the possibility of holding a presidential election during that period. Zelensky's term officially expired nearly a year ago, and he has consistently used martial law as justification for postponing the election. Russia has labeled Zelensky as \"illegitimate,\" asserting that the Ukrainian parliament is the true governing authority. On Tuesday, Zelensky introduced draft legislation in parliament, which suggests a three-month extension of martial law and general mobilization starting May 9. Under Ukrainian law, elections cannot be held while martial law is in effect, meaning the presidential election will remain suspended. If martial law were lifted, parliamentary elections could be held within 60 days, with presidential elections following within 90 days. The bills are expected to pass in parliament between April 15 and 18, according to Ukrainian MP Yaroslav Zheleznyak. There has been significant media speculation about Zelensky’s potential reelection bid. Earlier, Steve Witkoff, US President Donald Trump’s special envoy to the Middle East, hinted that elections would take place soon, though without providing specifics. Trump's remarks have referred to Zelensky as a \"dictator without elections.\" Despite this, Ukrainian officials, including David Arakhamia, head of Zelensky's faction in parliament, have dismissed plans for an election in the immediate future. Arakhamia mentioned that parliamentary parties have agreed to hold elections six months after martial law is lifted. Russian Foreign Minister Sergey Lavrov has criticized Western powers, alleging that European NATO members are working to ensure Zelensky's continued rule or, should he be ousted, to replace him with another leader who would maintain the \"Russophobic\" policies. MENAFN08052025000045015687ID1109522709 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:39:57",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/updates/pr/Menafn_News_Images%5Clocal_politics_56.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "negative",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "elections",
        • "government"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {
      • "article_id": "f6824788707a1f9c0cb0e83001105bd6",
      • "title": "Libro relata la trastienda de la pelea entre la KGB soviética y los nazis en Chile",
      • "link": "https://www.elmostrador.cl/noticias/sin-editar/2025/05/08/libro-relata-la-trastienda-de-la-pelea-entre-la-kgb-sovietica-y-los-nazis-en-chile/",
      • "keywords": null,
      • "creator": null,
      • "description": null,
      • "content": "Una serie de antecedentes históricos completamente desconocidos acerca de la instalación de la KGB (la famosa agencia de inteligencia de la Unión Soviética, a la cual perteneció Vladimir Putin) se relatan en la biografía de Iosif Grigulevich, que acaba de ser publicada por primera vez en español, por editorial Ceibo . Subtitulada El hombre de Stalin en América Latina , fue escrita por el periodista ruso Nil Nikandrov. El libro relata la participación de Grigulevich en los atentados destinados a asesinar a Trotsky en México, la instalación del líder operativo del primer atentado, el muralista David Alfaro Siqueiros, en Chillán, así como la instalación de lo que los estadounidenses conocieron como la red “Venona”, un aparataje de espionaje con base en Buenos Aires, dirigido por Grigulevich (que usaba el seudónimo de “Arthur”), y formado por chilenos, argentinos, entre otros, durante la Segunda Guerra Mundial. El libro además deja en evidencia el odio de los comunistas soviéticos hacia los nazis (a diferencia de las historias de redes sociales y de personas que insisten en asegurar que los nazis eran de izquierda). En efecto, Nikandrov cuenta cómo se decidió instalar una base del NKVD (como se llamaba antes la KGB) en Chile, a inicios de los años 40, entre otros motivos, debido a la gran actividad del NSDAP (siglas en alemán del Partido Nacional Socialista Obrero Alemán) en el país, así como de los espías del Abwehr, el aparataje de inteligencia militar dirigido por el legendario almirante Wilhelm Canaris (que conocía Chile a la perfección). De hecho, el texto relata el momento en que el agente que Grigulevich envió como jefe de la NKVD a Santiago, Leopoldo Arenal, más conocido como “Alexander”, tomó contacto con el PC local, pidiendo ayuda. Ante ello, Galo González fue designado como su enlace, preguntándole qué necesitaba. La respuesta de “Alexander” fue que requería personal “para sabotear el envío de materias primas a los nazis. Hay que parar el embarque de salitre y de cobre a los países del Eje”. Varios de los antecedentes al respecto fueron conseguidos por el autor del libro en una entrevista que realizó en Santiago al actualmente fallecido secretario general del Partido Comunista, Luis Corvalán, quien le dijo que “la Quinta Columna actuaba con extremo descaro en Chile”, en referencia a los nazis. Del mismo modo, y entre otros antecedentes, se relata la atención con que Alfaro Siqueiros –recluido en Chillán, mientras pintaba el famoso mural de la Escuela México– siguió el caso de unos supuestos cajones de armas que fueron vistos siendo llevados a un fundo cercano a la ciudad, en agosto de 1941, en lo que se pensaba eran actividades de parte de “un grupo secreto nazi que actuaba en la zona y preparaba un ataque armado”.",
      • "pubDate": "2025-05-08 04:39:54",
      • "pubDateTZ": "UTC",
      • "image_url": "https://www.elmostrador.cl/_templates/globals/img/placeholder.png",
      • "video_url": null,
      • "source_id": "elmostrador",
      • "source_name": "El Mostrador",
      • "source_priority": 239305,
      • "source_url": "https://www.elmostrador.cl",
      • "source_icon": "https://i.bytvi.com/domain_icons/elmostrador.png",
      • "language": "spanish",
      • -
        "country": [
        • "chile"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "awards and recognitions"
        ],
      • -
        "ai_region": [
        • "chile,south america"
        ],
      • "ai_org": null,
      • "duplicate": false
      },
    • -
      {},
    • -
      {
      • "article_id": "0f006d25df647a0405a87e3d4a04a55c",
      • "title": "Russia’s top MP labels EU’s Kallas as ‘crazy Russophobe’",
      • "link": "https://menafn.com/1109522708/Russias-top-MP-labels-EUs-Kallas-as-crazy-Russophobe",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN) Vyacheslav Volodin, Chairman of Russia's State Duma, has sharply criticized EU foreign policy chief Kaja Kallas for her comments about EU candidate countries attending Russia's May 9 ...",
      • "content": "( MENAFN ) Vyacheslav Volodin, Chairman of Russia's State Duma, has sharply criticized EU foreign policy chief Kaja Kallas for her comments about EU candidate countries attending Russia's May 9 Victory Day celebrations. He called Kallas a “crazy Russophobe” after she warned that countries seeking EU membership should refrain from participating in the 80th-anniversary events commemorating the defeat of Nazi Germany, as Russia is currently involved in a full-scale war in Europe. Kallas had issued the warning on Monday, suggesting that any participation in the Victory Day parades would not be taken lightly. Volodin responded on his Telegram account on Tuesday, calling Kallas' statement an ultimatum directed not only at EU member states but also at those countries negotiating EU accession. He argued that Kallas’ comments were disrespectful to the memory of those who sacrificed their lives to defeat fascism. Volodin further called for Kallas to be removed from her position and tried at a UN tribunal. Victory Day is one of Russia's most significant holidays, commemorated with a military parade in Red Square and a moment of silence to honor the 26.6 million Soviet lives lost in World War II. So far, Slovak Prime Minister Robert Fico is the only EU leader confirmed to attend the Moscow celebrations, with leaders from Serbia, Armenia, and other countries indicating their intention to join as well. Russian President Vladimir Putin has confirmed that Chinese President Xi Jinping will attend as part of a state visit. Additionally, Brazilian President Luiz Inácio Lula da Silva, as well as leaders from Vietnam, Cuba, Venezuela, Palestine, Azerbaijan, and other nations, have also accepted invitations. MENAFN08052025000045015687ID1109522708 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:37:02",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/updates/pr/Menafn_News_Images%5Clocal_media_241_menafn.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "negative",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "government"
        ],
      • -
        "ai_region": [
        • "russia,westmoreland parish,jamaica,north america",
        • "russia,ohio,united states of america,north america"
        ],
      • -
        "ai_org": [
        • "menafn",
        • "russia state duma"
        ],
      • "duplicate": false
      },
    • -
      {},
    • -
      {
      • "article_id": "714c11495d87c265a9d10c0b9d072a71",
      • "title": "Democratic bill risks additional sanctions on Russia",
      • "link": "https://menafn.com/1109522705/Democratic-bill-risks-additional-sanctions-on-Russia",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN) A bill introduced by Democratic lawmakers in the US House of Representatives on Monday proposes additional sanctions on Russia to support Ukraine, according to Reuters. Although the bill ...",
      • "content": "( MENAFN ) A bill introduced by Democratic lawmakers in the US House of Representatives on Monday proposes additional sanctions on Russia to support Ukraine, according to Reuters. Although the bill has not yet been made public, it is aimed at preventing President Donald Trump's administration from forming closer ties with Russia at Ukraine's expense. Sponsored by Rep. Gregory Meeks, the ranking member of the House Foreign Affairs Committee, the bill mandates continued US involvement in Ukraine's reconstruction, ongoing military aid through loans and financing, and sanctions targeting Russian financial institutions, oil and mining sectors, as well as specific Russian officials. Sources indicated that the bill is expected to face challenges in the Republican-controlled House. However, its primary goal is to influence negotiations on Ukraine-related legislation that will eventually be passed, with some provisions likely to be included in a broader Ukraine-focused package. While Trump has expressed interest in pursuing mutually beneficial relations with Russia, he has also warned that he may escalate pressure on Moscow if it does not negotiate in good faith over Ukraine. Russia has indicated a willingness to resolve the conflict but highlighted Ukraine's violations of a US-proposed moratorium on attacks against energy infrastructure. Earlier in April, a bipartisan group introduced separate legislation aimed at imposing heavy sanctions on Russia. Critics have accused Trump of adopting a soft approach to Russia in his efforts to rebuild diplomatic ties, while supporters of Ukraine argue that shifting blame from Moscow distorts the history of the conflict. Additionally, the Trump administration is working to finalize a minerals deal with Ukraine, believing access to the country's natural resources will help recoup some of the billions spent on the conflict under former President Joe Biden. Trump has framed the situation as an example of Ukraine and Europe taking advantage of American support. MENAFN08052025000045015687ID1109522705 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:34:03",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/updates/pr/Menafn_News_Images%5Clocal_politics_1021.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "negative",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "government"
        ],
      • -
        "ai_region": [
        • "russia,ohio,united states of america,north america",
        • "russia,westmoreland parish,jamaica,north america"
        ],
      • -
        "ai_org": [
        • "us house of representatives",
        • "menafn"
        ],
      • "duplicate": false
      },
    • -
      {
      • "article_id": "06b7498a303b09aadf0e8e28c9b82d86",
      • "title": "Armenian Premier declares country prepared to sign peace agreement with Azerbaijan",
      • "link": "https://menafn.com/1109522704/Armenian-Premier-declares-country-prepared-to-sign-peace-agreement-with-Azerbaijan",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN) Armenian Prime Minister Nikol Pashinyan has declared that Armenia is prepared to sign a peace agreement with Azerbaijan and dissolve the OSCE Minsk Group, a long-standing mediation ...",
      • "content": "( MENAFN ) Armenian Prime Minister Nikol Pashinyan has declared that Armenia is prepared to sign a peace agreement with Azerbaijan and dissolve the OSCE Minsk Group, a long-standing mediation framework for the Nagorno-Karabakh conflict. This move comes after Azerbaijan regained control of the disputed region in 2023, leading to the departure of the ethnic Armenian population and the collapse of the region’s separatist government. Following this, Azerbaijan demanded that the Minsk Group be formally disbanded as part of any peace deal. Speaking before the Armenian parliament, Pashinyan acknowledged Azerbaijan’s position regarding the dissolution of the Minsk Group, noting that with the end of the Nagorno-Karabakh conflict, the group no longer serves a purpose. He proposed that Armenia and Azerbaijan sign the peace agreement and dissolve the Minsk Group on the same day. Azerbaijan has insisted that any peace deal include the disbandment of the Minsk Group and amendments to Armenia’s constitution, which it claims includes territorial assertions against Azerbaijan. The OSCE Minsk Group, co-chaired by Russia, France, and the United States, was established in the 1990s but became largely inactive after the 2020 Nagorno-Karabakh war and Azerbaijan's military action in 2023. Russian Foreign Minister Sergey Lavrov had previously acknowledged the group’s inactivity, attributing it to the efforts of the US and France. Since then, the conflict resolution process has primarily been handled through direct discussions between the leaders of Armenia, Azerbaijan, and Russia. Armenian Foreign Minister Ararat Mirzoyan also confirmed that both countries recognize each other's territorial integrity based on their Soviet-era borders and referred to the peace treaty talks as a historic development. While the exact timeline for these discussions is yet to be determined, consultations are expected to begin soon. MENAFN08052025000045015687ID1109522704 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:33:24",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/updates/pr/Menafn_News_Images%5Clocal_politics_1014.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "positive",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "government"
        ],
      • -
        "ai_region": [
        • "armenia,antioquia,colombia,south america",
        • "armenia,quindío,colombia,south america",
        • "armenia,sonsonate department,el salvador,north america",
        • "azerbaijan,asia",
        • "armenia,yoro department,honduras,north america"
        ],
      • -
        "ai_org": [
        • "menafn"
        ],
      • "duplicate": false
      },
    • -
      {
      • "article_id": "1f2e6c913169943100bc6b22a6c68ce3",
      • "title": "Acer Announces Q1'25 Operating Income At NT$1.04 Billion, Up 33.0% Year-On-Year",
      • "link": "https://menafn.com/1109522700/Acer-Announces-Q125-Operating-Income-At-NT104-Billion-Up-330-Year-On-Year",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - PR Newswire) Margins for gross profit and operating income grow year-on-year TAIPEI, May 8, 2025 /PRNewswire/ -- Acer Inc. (TWSE: 2353) announced its financial results for the ...",
      • "content": "( MENAFN - PR Newswire) Margins for gross profit and operating income grow year-on-year TAIPEI, May 8, 2025 /PRNewswire/ -- Acer Inc. (TWSE: 2353) announced its financial results for the first quarter of 2025. Consolidated revenues reached NT$61.34 billion, up 4.3% year-on-year (YoY); gross profits reached NT$6.48 billion with 4.6% growth YoY and 10.6% margin; operating income was NT$1.04 billion, up 33.0% YoY, with 1.7% margin; and net income [1] was NT$515 million with earnings-per-share of NT$0.17. In the first quarter, businesses other than personal computers [2] and displays contributed 31.6% of total revenues, and public subsidiaries contributed 50.1% of operating income. At Computex Taipei held from May 20-23, Acer will showcase its range of innovations including AI PCs, displays, gaming and connectivity portfolio, as well as smart solutions from its subsidiaries. [1] Net income is reported as profit-after-tax in Acer's financial statements [2] Personal computers business includes desktop and notebooks About Acer Founded in 1976, Acer is one of the world's top technology companies with a presence in more than 160 countries. The company continues to evolve by embracing innovation across its offerings, which include computers and displays, while branching out to new businesses. Acer is also committed to sustainable growth, exploring new opportunities that align with its environmental and social responsibilities. The Acer Group employs over 9,000 employees that contribute to the research, design, marketing, sales and support of products, solutions, and services that break barriers between people and technology. Visit for more information. © 2025 Acer Inc. All rights reserved. Acer and the Acer logo are registered trademarks of Acer Inc. Other trademarks, registered trademarks, and/or service marks, indicated or otherwise, are the property of their respective owners. All offers subject to change without notice or obligation and may not be available through all sales channels. Prices listed are manufacturer suggested retail prices and may vary by location. Applicable sales tax extra. SOURCE Acer WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?440k+ Newsrooms & Influencers9k+ Digital Media Outlets270k+ Journalists Opted InGET STARTED MENAFN08052025003732001241ID1109522700 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:46",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "positive",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "financial markets"
        ],
      • "ai_region": null,
      • -
        "ai_org": [
        • "acer"
        ],
      • "duplicate": true
      },
    • -
      {
      • "article_id": "118bbf61e36bfb8203156ec7b62e3e94",
      • "title": "Hyxipower Goes Beyond With Automotive-Grade Safety At Intersolar 2025",
      • "link": "https://menafn.com/1109522702/Hyxipower-Goes-Beyond-With-Automotive-Grade-Safety-At-Intersolar-2025",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - PR Newswire)Driven by the \"Spirit of Super Five\" - Super Service, Super Usability, Super Performance, Super ValuE, and Super Reliability - HYXiPOWER continues to deliver solutions that ...",
      • "content": "( MENAFN - PR Newswire) Driven by the \"Spirit of Super Five\" - Super Service, Super Usability, Super Performance, Super ValuE, and Super Reliability - HYXiPOWER continues to deliver solutions that go beyond expectation, leading the way towards a cleaner, greener future through exceptional simplicity, advanced safety, and innovation. At booth B4-170, HYXiPOWER officially launched its innovation-driven All-in-One ESS, setting a new industry benchmark by achieving zero injection without external meters or CTs needed. Engineered with automotive-grade standards, the system integrates A+ grade cells, advanced BMS, smoke detection, and explosion-proof valves. Its plug-and-play design seamlessly fits existing distribution boxes without rewiring and works effortlessly with third-party inverters. Available from 6 kW to 15 kW, and expandable from 10 kWh to 25 kWh, it supports 160% PV input overmatching, 150% instant off-grid overload with three-phase unbalanced output. Built-in AFCI and Type II surge protection deliver intelligent, durable, and efficient energy storage-all in one. Beyond Applications: Innovation for Every Needs Highlighting its commitment to full-scenario coverage, HYXiPOWER also introduced its Air-Cooling ESS and Balcony Micro Storage System. The Air-Cooling ESS, built with A+ grade cells, ensures high safety and reliability. Its flexible, plug-and-play design supports up to eight units in parallel, with integrated EMS and remote O&M simplifying deployment and maintenance. The Balcony Micro Storage System offers a 2,560Wh battery capacity (expandable to three units, maximum 10.24kWh), delivering up to 1,200W output and supporting low-power DC devices. Its compatibility with microinverters and simple installation further underline HYXiPOWER's pursuit of usability. \"Energy belongs to everyone. At HYXiPOWER, our products design with purpose - prioritizing safety, simplicity, and seamless experience, grounded in automotive-grade engineering,\" said Han Yin, General Manager of HYXiPOWER Europe. Beyond Collaboration: Growing Stronger with Global Partners HYXiPOWER also celebrated partnerships with global partners, including Multipunkt GmbH (Germany), EVOLUSOLAR ENERGY (France), BM Energy (Netherlands), CONNECTOWAY (Brazil) etc., strengthening its global presence and advancing the adoption of clean energy. David Shen, General Manager of HYXiPOWER Overseas Business Center, stated, \"These collaborations has deepened our global network. Together with our partners, we go beyond today's needs, act as both guardians and driving forces behind the global transition to sustainable energy.\" Photo - MENAFN08052025003732001241ID1109522702 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:46",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/updates/pr/2025-05/08/PN_4cf17image_story.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "positive",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "automotive"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": true
      },
    • -
      {
      • "article_id": "41b0aedeeb9d05e770485b5d0ed72c31",
      • "title": "Nordic Bioscience Announces PRO-C3 Launched By Roche Diagnostics On Cobas Analysers",
      • "link": "https://menafn.com/1109522697/Nordic-Bioscience-Announces-PRO-C3-Launched-By-Roche-Diagnostics-On-Cobas-Analysers",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - PR Newswire)The nordicPRO-C3TM biomarker is already validated in Nordic Bioscience CAP-CLIA certified laboratory in Denmark. This demonstrates that Nordic Bioscience is dedicated to ...",
      • "content": "( MENAFN - PR Newswire)The nordicPRO-C3TM biomarker is already validated in Nordic Bioscience CAP-CLIA certified laboratory in Denmark. This demonstrates that Nordic Bioscience is dedicated to helping patients in a precision medicine driven approach, and our Platform provides the quality needed for regulatory approval. Nordic Bioscience's scientists have over that last 10 years published more than 250 scientific papers on PRO-C3 making us the leading place for research within PRO-C3 and fibrotic related diseases. PRO-C3 is the first of the Nordic Bioscience-biomarkers from our fibrosis panel which has been CE-approved. 40% of deaths in the western world are associated with alterations of organs such as the liver, and we provide the tools to quantify this. These are the tools of modern clinical chemistry. \"The Elecsys PRO-C3 test is the first test launched from the collaboration between Nordic Bioscience and Roche Diagnostics. We are proud that our technology becomes globally available to make a difference for patients.\" said Morten Karsdal, CEO of Nordic Bioscience. About PRO-C3 PRO-C3 was invented by Nordic Bioscience and has up until now been available as a service performed in Nordic Bioscience's laboratory in Denmark using the nordicPRO-C3TM test. The Elecsys PRO-C3 test is developed under a license agreement between Nordic Bioscience and Roche Diagnostics. For more information including scientific information on PRO-C3 see About Nordic Bioscience Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. We are engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting. For more information about Nordic Bioscience, visit us at For product related inquires please use contact Photo - Logo - MENAFN08052025003732001241ID1109522697 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:46",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/updates/pr/2025-05/08/PN_479f3image_story.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "research"
        ],
      • "ai_region": null,
      • -
        "ai_org": [
        • "pr newswire",
        • "menafn",
        • "nordic bioscience",
        • "roche diagnostics",
        • "cobas analysers"
        ],
      • "duplicate": true
      },
    • -
      {
      • "article_id": "cde8bff0cf9fde30d8c339ca6f4169f1",
      • "title": "Norway Data Center Market Investment Analysis Report 2025-2030 | Norway Leverages Cold Climate To Enhance Data Center Efficiency And Cut Costs",
      • "link": "https://menafn.com/1109522696/Norway-Data-Center-Market-Investment-Analysis-Report-2025-2030-Norway-Leverages-Cold-Climate-To-Enhance-Data-Center-Efficiency-And-Cut-Costs",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - GlobeNewsWire - Nasdaq) Norway's data center market, valued at USD 1.55 billion in 2024, is projected to reach USD 2.79 billion by 2030, growing at a 10.29% CAGR. Key operators like Green ...",
      • "content": "( MENAFN - GlobeNewsWire - Nasdaq) Norway's data center market, valued at USD 1.55 billion in 2024, is projected to reach USD 2.79 billion by 2030, growing at a 10.29% CAGR. Key operators like Green Mountain innovate with liquid cooling, heat recovery, and renewable energy. Global leaders like Microsoft and AWS fuel investment, aiding sustainability and operational efficiency. Explore more about Norway's thriving data center landscape. Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Norway Data Center Market - Investment Analysis & Growth Opportunities 2025-2030\" report has been added to ResearchAndMarkets.com's offering. Norway's Data Center Market was valued at USD 1.55 billion in 2024, and is projected to reach USD 2.79 billion by 2030, rising at a CAGR of 10.29%. The Norwegian data center market has the presence of several global support infrastructure providers that will increase its competitiveness in the market. Some of the support infrastructure vendors present in the Norway data center market include ABB, Caterpillar, Cummins, Delta Electronics, Eaton, Legrand, Piller Power Systems, Rittal, Rolls-Royce, Schneider Electric, STULZ, Vertiv, and others. Some of the key colocation data center investors in the Norway data center market include Green Mountain, STACK Infrastructure, Bulk Infrastructure, AQ Compute, Orange Business, Lefdal Mine Data Centers, Telia, and others. Norway's data center market has several local and global construction contractors operating in the market including AECOM, Arup, Coromatic AB, COWI, Designer Group, Elecnor Group, HDR Architecture, Keysource, Mercury, Mecwide, RED Engineering Design, Rider Levett Bucknall RLB, Skanska, Sweco, Turner & Townsend, YIT and others that have been offering their construction, engineering and installation services in the data center market in the country. KEY HIGHLIGHTS Operators in the Norway data center market, such as Green Mountain and Bulk Infrastructure Group AS, are adopting advanced liquid cooling technologies for efficient thermal management; furthermore, they are implementing heat recovery systems to channel the excess heat generated in their facilities to nearby locations to enhance sustainability efforts across the country. Sustainability in the Norway data center market is supported by growing investments in renewable energy and energy-efficient technologies, with operators increasingly adopting Power Purchase Agreements (PPAs). The data center companies are focusing on innovative construction techniques to reduce their carbon impact by replacing materials, including steel and concrete, with timber wood; furthermore, operators are also installing solar roofs in their facilities. The government is regulating data centers under electronic communication laws to enhance digital security and protect national interests. This approach also encourages leveraging Norway's renewable energy resources to drive sustainable growth within the industry. Global cloud operators, such as Microsoft, Amazon Web Services (AWS), and Google Cloud, are driving significant data center investments in Norway due to the growing demand for cloud services. Colocation providers, such as STACK Infrastructure, Lefdal Mine Datacenter, and Bulk Infrastructure Group AS, are actively expanding their operations to address the increasing demand for reliable data center infrastructure across the country. In 2024, the Norway data center market witnessed new entrants such as Keysource and Namsos DataSenter, and Google. Norway's focus on utilizing waste heat to enhance efficiency and environmental responsibility aligns with the global sustainability trends, attracting the attention of eco-conscious investors and businesses. Norway's naturally cold climate enables efficient free cooling for data centers, significantly reducing the need for mechanical cooling systems and lowering operational costs and energy consumption. REPORT SCOPE Market size available in the investment area, power capacity, and the Norway colocation market revenue. An assessment of the data center investment in Norway by colocation, hyperscale, and enterprise operators. Data center investments in the area (square feet) and power capacity (MW) across cities in the country. A detailed study of the existing Norway data center market landscape, an in-depth market analysis, and insightful predictions about the Norway data center market size during the forecast period. Snapshot of existing and upcoming third-party data center facilities in Norway Facilities Covered (Existing): 33 Facilities Identified (Upcoming): 09 Coverage: 9+ Cities Existing vs. Upcoming (Data Center Area) Existing vs. Upcoming (IT Load Capacity) Data center colocation market in Norway Colocation Market Revenue & Forecast (2021-2030) Retail vs Wholesale Colocation Market Revenue & Forecast (2021-2030) Retail & Wholesale Colocation Pricing The Norway data center landscape market investments are classified into IT, power, cooling, and general construction services with sizing and forecast. A comprehensive analysis of the latest trends, growth rate, potential opportunities, growth restraints, and prospects for the market. Business overview and product offerings of prominent IT infrastructure providers, construction contractors, support infrastructure providers, and investors operating in the market. A transparent research methodology and the analysis of the demand and supply aspects of the market. EXISTING VS. UPCOMING DATA CENTERS Existing Facilities in the Region (Area and Power Capacity) Oslo Other Cities List of Upcoming Facilities in the Region (Area and Power Capacity) Oslo Other Cities IT Infrastructure Providers Arista Networks Cisco Systems Dell Technologies Hewlett Packard Enterprise Hitachi Vantara Huawei Technologies IBM Juniper Networks Lenovo NetApp NetNordic Group AS Oracle Pure Storage Super Micro Computer Data Center Construction Contractors & Sub-Contractors AECOM Arup Coromatic AB COWI CTS Group Designer Group Elecnor Group HDR Architecture Keysource Kirby Group Engineering Marsh Mecwide Mercury Olaris AS Ramboll RED Engineering Design Rider Levett Bucknall (RLB) Skanska Sweco Turner & Townsend YIT Support Infrastructure Providers ABB Alfa Laval Austin Hughes Electronics Carrier Caterpillar Comsys Condair Group Cummins DEIF Delta Electronics Eaton FlaktGroup GE Vernova HITEC Power Protection Johnson Controls Rehlko Legrand Mitsubishi Electric Perkins Engine Piller Power Systems Rittal Rolls-Royce Schneider Electric Siemens Socomec Group STULZ Swegon Trane Technologies Vertiv Data Center Investors AQ Compute Orange Business Bulk Infrastructure Green Mountain Lefdal Mine Data Centers STACK Infrastructure STORESPEED Telia New Entrants Keysource & Namsos DataSenter Google Key Attributes: Report Attribute Details No. of Pages 123 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.55 Billion Forecasted Market Value (USD) by 2030 $2.79 Billion Compound Annual Growth Rate 10.2% Regions Covered Norway The report includes the investment in the following areas: IT Infrastructure Servers Storage Systems Network Infrastructure Electrical Infrastructure UPS Systems Generators Transfer Switches & Switchgears PDUs Other Electrical Infrastructure Mechanical Infrastructure Cooling Systems Rack Cabinets Other Mechanical Infrastructure Cooling Systems CRAC & CRAH Units Chiller Units Cooling Towers, Condensers & Dry Coolers Other Cooling Units General Construction Core & Shell Development Installation & Commissioning Services Engineering & Building Design Fire Detection & Suppression Systems Physical Security Data Center Infrastructure Management (DCIM) Tier Standard Tier I & Tier II Tier III Tier IV For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Norwegian Data Center Market CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 MENAFN08052025004107003653ID1109522696 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:42",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "technology"
        ],
      • -
        "ai_region": [
        • "norway,maine,united states of america,north america",
        • "norway,michigan,united states of america,north america"
        ],
      • -
        "ai_org": [
        • "norway data center market investment"
        ],
      • "duplicate": true
      },
    • -
      {
      • "article_id": "6fc6e3ed8d5d37d438cbb4fcee5a497c",
      • "title": "Tecentriq (Atezolizumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2034",
      • "link": "https://menafn.com/1109522693/Tecentriq-Atezolizumab-Market-Research-Report-2025-Epidemiology-Pipeline-Analysis-Market-Insights-Forecasts-2019-2034",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Tecentriq (Atezolizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts\" report has ...",
      • "content": "( MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Tecentriq (Atezolizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts\" report has been added to ResearchAndMarkets.com's offering. This Tecentriq (Atezolizumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. Market growth during the historic period can be attributed to the increased demand for minimal residual disease (MRD) monitoring, the importance of real-world evidence, rising interest in novel drug formulations, high rates of triple-negative breast cancer, and the growing use in first-line treatment settings. Major players operating in the tecentriq (atezolizumab) market are Roche Holding AG, and Chugai Pharmaceutical Co. Ltd. North America was the largest region in the tecentriq (atezolizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. Factors driving growth in the forecast period include an increasing focus on early detection and prevention, growing cancer survival rates, expanding global cancer research initiatives, higher healthcare spending in developing economies, and increased awareness among patients and physicians. Key trends in the forecast period include the integration of artificial intelligence (AI), telemedicine and remote monitoring, regulatory innovations, advancements in biomarker discovery, and innovative drug development. The increasing prevalence of cancer is expected to drive the growth of the tecentriq (atezolizumab) market. This rise in cancer cases can be attributed to factors such as an aging population, better detection techniques, lifestyle changes, environmental exposures, and improved survival rates, all contributing to more people being diagnosed and living with cancer. Tecentriq (atezolizumab) is vital for cancer treatment as it utilizes the immune system to combat cancer by blocking PD-L1, a protein that allows tumors to evade immune detection. This enables the immune system's T-cells to recognize and destroy cancer cells more effectively. For example, in January 2024, the American Cancer Society reported a rise in cancer cases, with the number of new cases increasing to 2,001,140 from 1,958,310 in 2023, a growth of 2.19%. As a result, the growing prevalence of cancer is driving the tecentriq (atezolizumab) market forward. A key trend in the tecentriq (atezolizumab) market is the development of innovative products, such as intravenous formulations of atezolizumab, aimed at ensuring precise dosing, rapid systemic absorption, and consistent therapeutic levels. The intravenous formulation is a liquid preparation administered directly into the bloodstream via infusion, designed to efficiently deliver the monoclonal antibody for systemic cancer treatment. For example, in September 2024, Genentech Inc. received approval from the U.S. Food and Drug Administration for atezolizumab and hyaluronidase-tqjs for subcutaneous injection. Tecentriq, the first subcutaneous anti-PD-L1 therapy approved in the U.S., offers a distinct advantage with a faster administration time of approximately 7 minutes compared to the 30-60 minutes required for intravenous infusion, while maintaining comparable efficacy in drug exposure and overall response rates, as demonstrated in the IMscin001 trial. It is approved for various adult cancers, including NSCLC, SCLC, melanoma, hepatocellular carcinoma, and alveolar soft part sarcoma. In October 2024, Lonza Group AG, a Switzerland-based pharmaceutical, biotechnology, and nutrition company, acquired Roche's Vacaville large-scale biologics manufacturing facility for $1.2 billion. This acquisition establishes a strong West Coast manufacturing presence near the San Francisco biotech hub, complementing Lonza's existing East Coast site in Portsmouth, New Hampshire, and its global network in Europe and Asia Pacific. The expansion significantly strengthens Lonza's ability to manufacture late-stage clinical and commercial products and support the production of new molecules approaching commercialization. Roche Holding AG, a Switzerland-based manufacturer of pharmaceuticals and biologics, produces Tecentriq (atezolizumab). Key Topics Covered: 1. Executive Summary 2. Tecentriq (Atezolizumab) Market Characteristics 3. Tecentriq (Atezolizumab) Market Biologic Drug Characteristics 3.1. Molecule Type 3.2. Route of Administration (ROA) 3.3. Mechanism of Action (MOA) 3.4. Safety and Efficacy 4. Tecentriq (Atezolizumab) Market Trends and Strategies 5. Tecentriq (Atezolizumab) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market 6. Global Tecentriq (Atezolizumab) Growth Analysis and Strategic Analysis Framework 6.1. Global Tecentriq (Atezolizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints) 6.2. Analysis of End Use Industries 6.3. Global Tecentriq (Atezolizumab) Market Growth Rate Analysis 6.4. Global Tecentriq (Atezolizumab) Historic Market Size and Growth, 2019-2024, Value ($ Billion) 6.5. Global Tecentriq (Atezolizumab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion) 6.6. Global Tecentriq (Atezolizumab) Total Addressable Market (TAM) 7. Global Tecentriq (Atezolizumab) Market Pricing Analysis & Forecasts 8. Tecentriq (Atezolizumab) Market Segmentation 8.1. Global Tecentriq (Atezolizumab) Market, Segmentation by Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion PD-L1 Inhibitors PD-1 Inhibitors CTLA-4 Inhibitors Immunomodulators Other Drug Classes 8.2. Global Tecentriq (Atezolizumab) Market, Segmentation by Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Lung Cancer Bladder Cancer Melanoma Hodgkin's Lymphoma Head and Neck Cancer Other Indications 8.3. Global Tecentriq (Atezolizumab) Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Hospital Pharmacies Retail Pharmacies Online Pharmacies 8.4. Global Tecentriq (Atezolizumab) Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Hospitals Homecare Specialty Clinics Other End Users 9. Global Tecentriq (Atezolizumab) Market Epidemiology of Clinical Indications 9.1. Drug Side Effects 9.2. Incidence and Prevalence of Clinical Indications 10. Tecentriq (Atezolizumab) Market Regional and Country Analysis 10.1. Global Tecentriq (Atezolizumab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 10.2. Global Tecentriq (Atezolizumab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Companies Featured Roche Holding AG Chugai Pharmaceutical Co. Ltd For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 MENAFN08052025004107003653ID1109522693 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:42",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • "ai_tag": null,
      • -
        "ai_region": [
        • "dublin,ohio,united states of america,north america",
        • "dublin,virginia,united states of america,north america",
        • "dublin,california,united states of america,north america",
        • "dublin,new hampshire,united states of america,north america",
        • "dublin,pennsylvania,united states of america,north america",
        • "dublin,texas,united states of america,north america",
        • "dublin,georgia,united states of america,north america"
        ],
      • "ai_org": null,
      • "duplicate": true
      },
    • -
      {
      • "article_id": "682f53084494ebe0c08ee08acfd41173",
      • "title": "Vectibix (Panitumumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2034",
      • "link": "https://menafn.com/1109522690/Vectibix-Panitumumab-Market-Research-Report-2025-Epidemiology-Pipeline-Analysis-Market-Insights-Forecasts-2019-2034",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - GlobeNewsWire - Nasdaq) This Vectibix (panitumumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It ...",
      • "content": "( MENAFN - GlobeNewsWire - Nasdaq) This Vectibix (panitumumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Vectibix (panitumumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts\" report has been added to ResearchAndMarkets.com's offering. The key players operating in the vectibix (panitumumab) market is Amgen Inc. North America was the largest region in the vectibix (panitumumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The growth observed in the historical period can be credited to improvements in overall survival rates in clinical trials, favorable reimbursement policies in developed markets, financial assistance programs for patients, educational efforts for oncologists regarding genetic testing, and greater access to advanced diagnostics in developing regions. Market growth during the forecast period is driven by the increasing prevalence of metastatic colorectal cancer (mCRC) worldwide, a growing emphasis on personalized medicine, rising healthcare spending in emerging markets, higher adoption of biologics in oncology, and a stronger focus on patient quality of life. Key trends during the forecast period include advancements in anti-EGFR therapies, partnerships between pharmaceutical companies, the integration of advanced diagnostic tools, development of companion diagnostics, and the adoption of next-generation sequencing. The increasing prevalence of colorectal cancer is expected to drive the growth of the vectibix (panitumumab) market in the coming years. Colorectal cancer, which begins in the colon or rectum, is influenced by factors such as aging, genetic predispositions, and environmental influences. The rising incidence of colorectal cancer is linked to an aging population, better survival rates, and improved detection methods. Vectibix (panitumumab), a monoclonal antibody, targets and inhibits the epidermal growth factor receptor (EGFR) to slow tumor growth and progression in patients with wild-type KRAS tumors. This offers an effective treatment for patients who do not respond to conventional chemotherapy. According to the World Health Organization (WHO), the global burden of colorectal cancer is expected to increase significantly by 2040, with 3.2 million new cases annually, a 63% rise. This growing prevalence is poised to drive the demand for vectibix. The rising demand for personalized medicine is a key factor propelling the growth of the vectibix (panitumumab) market. Personalized medicine tailors treatments based on individual patient characteristics, including genetic profiles. Advances in genomic technologies, improved understanding of molecular biology, and the availability of precision diagnostic tools have made personalized therapies more common. Vectibix is used as a personalized treatment for metastatic colorectal cancer by targeting the EGFR on cancer cells, particularly in patients whose tumors express wild-type EGFR. This targeted approach improves therapeutic efficacy and minimizes side effects. For example, in February 2023, the Personalized Medicine Coalition highlighted that the FDA approved several important indications for in vitro diagnostic testing, contributing to the rising demand for personalized medicine. This trend further supports the growth of the vectibix market. A significant trend in the vectibix market is the development of molecular diagnostic products, such as companion diagnostic kits, which help identify the most suitable patients for targeted therapies. Companion diagnostic kits detect specific biomarkers or genetic mutations, ensuring that treatments like Vectibix are given to patients who are most likely to benefit. In October 2023, EntroGen Inc. received FDA approval for the CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix. This kit, which detects mutations in KRAS and NRAS genes, helps clinicians identify patients who would benefit from Vectibix, ensuring more effective treatment while minimizing unnecessary side effects and costs. This trend towards personalized diagnostics is enhancing the precision of Vectibix therapy and contributing to the market's growth. Key Topics Covered: 1. Executive Summary 2. Vectibix (panitumumab) Market Characteristics 3. Vectibix (panitumumab) Market Biologic Drug Characteristics 3.1. Molecule Type 3.2. Route of Administration (ROA) 3.3. Mechanism of Action (MOA) 3.4. Safety and Efficacy 4. Vectibix (panitumumab) Market Trends and Strategies 5. Vectibix (panitumumab) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market 6. Global Vectibix (panitumumab) Growth Analysis and Strategic Analysis Framework 6.1. Global Vectibix (panitumumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints) 6.2. Analysis of End Use Industries 6.3. Global Vectibix (panitumumab) Market Growth Rate Analysis 6.4. Global Vectibix (panitumumab) Historic Market Size and Growth, 2019-2024, Value ($ Billion) 6.5. Global Vectibix (panitumumab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion) 6.6. Global Vectibix (panitumumab) Total Addressable Market (TAM) 7. Global Vectibix (panitumumab) Market Pricing Analysis & Forecasts 8. Vectibix (panitumumab) Market Segmentation 8.1. Global Vectibix (panitumumab) Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Hospital Pharmacies Online Pharmacies 8.2. Global Vectibix (panitumumab) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Colorectal Cancer Treatment Other Cancer Treatments 8.3. Global Vectibix (panitumumab) Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Hospitals Clinics Ambulatory Surgical Centers 9. Global Vectibix (panitumumab) Market Epidemiology of Clinical Indications 9.1. Drug Side Effects 9.2. Incidence and Prevalence of Clinical Indications 10. Vectibix (panitumumab) Market Regional and Country Analysis 10.1. Global Vectibix (panitumumab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 10.2. Global Vectibix (panitumumab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 MENAFN08052025004107003653ID1109522690 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:42",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "technology"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": true
      },
    • -
      {
      • "article_id": "3b401c709e62cbef59437e9e73b2c438",
      • "title": "Perjeta (Pertuzumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2034",
      • "link": "https://menafn.com/1109522694/Perjeta-Pertuzumab-Market-Report-2025-Epidemiology-Pipeline-Analysis-Market-Insights-Forecasts-2019-2034",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - GlobeNewsWire - Nasdaq) Explore the burgeoning Perjeta (Pertuzumab) market, driven by rising breast cancer cases and advancements in oncology treatments. Our in-depth report covers market ...",
      • "content": "( MENAFN - GlobeNewsWire - Nasdaq) Explore the burgeoning Perjeta (Pertuzumab) market, driven by rising breast cancer cases and advancements in oncology treatments. Our in-depth report covers market size, growth, segmentation, and regional insights, spotlighting trends like ADCs, biosimilars, subcutaneous therapies, and key players. Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Perjeta (Pertuzumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts\" has been added to ResearchAndMarkets.com's offering. The Perjeta (Pertuzumab) market report provides a comprehensive analysis of various key market aspects such as size, growth potential, and segmentation. It explores significant regions and leading countries, presenting historical data and projecting future growth. The competitive landscape is dissected along with market share insights, emerging trends, and strategic developments influencing the market dynamics. Historically, the market has experienced growth due to the adoption of oncology treatments and the increasing demand for antibody-drug conjugates (ADCs). Additionally, there's a growing need for targeted, less toxic therapies, alongside developments in personalized medicine. The future forecast indicates that this growth will continue, driven by rising breast cancer incidences and heightened interest in ADCs for hematologic malignancies. Moreover, cancer rates are escalating, unmet medical needs are recognized, and pharmaceutical R&D in cancer immunotherapy is expanding. Significant trends include the use of biosimilars in oncology, advancements in drug formulations, and breakthroughs in cancer immunotherapy research, emphasizing combination therapies. An uptick in breast cancer cases is a critical driver for market growth, particularly with lifestyle changes leading to higher obesity rates and sedentary behaviors, coupled with the enhancement of early detection methods. Perjeta (pertuzumab) is instrumental in treating HER2-positive breast cancer by targeting the HER2 receptor, often used in conjunction with trastuzumab and chemotherapy for improved outcomes. Recent reports, such as that from the UK-based Ray of Light Wales, project significant growth in breast cancer survivor numbers, underscoring the market's expansion potential. Technological advancements are a key market trend, including the development of subcutaneous combination therapies aimed at enhancing patient outcomes and treatment convenience. For instance, Chugai Pharmaceutical Co., Ltd. introduced Phesgo in November 2023, a notable subcutaneous treatment for HER2-positive cancers, combining pertuzumab, trastuzumab, and vorhyaluronidase alfa for a fast, efficient administration method. In June 2024, a strategic partnership between Zydus Pharmaceuticals and Dr. Reddy's Laboratories was announced to boost the accessibility of pertuzumab biosimilars in India, aiming to improve affordability and availability of this critical treatment for HER2-positive breast cancer patients. Roche Holding AG stands out as a key player in this market. Geographically, North America was the largest region in the Perjeta market in 2024, while Asia-Pacific is predicted to show the fastest growth. The market spans regions including Asia-Pacific, Western and Eastern Europe, North and South America, and the Middle East and Africa, with countries such as Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain involved. Perjeta (pertuzumab), a targeted therapy for specific breast cancer types, is a monoclonal antibody developed using recombinant DNA technology and primarily sold through hospital pharmacies, retail pharmacies, and online platforms. This market consists of key products like herceptin, docetaxel, paclitaxel, and carboplatin, based on 'factory gate' values, including related services offered by manufacturers. Key Topics Covered: 1. Executive Summary 2. Perjeta (Pertuzumab) Market Characteristics 3. Perjeta (Pertuzumab) Market Biologic Drug Characteristics 3.1. Molecule Type 3.2. Route of Administration (ROA) 3.3. Mechanism of Action (MOA) 3.4. Safety and Efficacy 4. Perjeta (Pertuzumab) Market Trends and Strategies 5. Macro Economic Scenario Impact on the Market 6. Global Growth Analysis and Strategic Analysis Framework 6.1. Global PESTEL Analysis 6.2. Analysis of End Use Industries 6.3. Global Growth Rate Analysis 6.4. Historic Market Size and Growth 6.5. Forecast Market Size and Growth 6.6. Total Addressable Market (TAM) 7. Market Pricing Analysis & Forecasts 8. Market Segmentation 8.1. Segmentation by Type 8.2. Segmentation by Product 8.3. Segmentation by Indication 8.4. Segmentation by Distribution Channel 9. Market Epidemiology of Clinical Indications 9.1. Drug Side Effects 9.2. Incidence and Prevalence of Clinical Indications 10. Market Regional and Country Analysis 10.1. Split by Region 10.2. Split by Country For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 MENAFN08052025004107003653ID1109522694 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:42",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "technology"
        ],
      • "ai_region": null,
      • -
        "ai_org": [
        • "perjeta",
        • "pertuzumab"
        ],
      • "duplicate": true
      },
    • -
      {
      • "article_id": "72768ae2d38c3709cff7f04704f78181",
      • "title": "Reopro (Abciximab) Market Research Report 2025: Geriatric Population Boom Boosts Demand - Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2034",
      • "link": "https://menafn.com/1109522691/Reopro-Abciximab-Market-Research-Report-2025-Geriatric-Population-Boom-Boosts-Demand-Epidemiology-Pipeline-Analysis-Market-Insights-Forecasts-2019-2034",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - GlobeNewsWire - Nasdaq) The ReoPro (Abciximab) market report offers comprehensive analysis, covering market size, growth potential, and segmentation by region and country. Key drivers ...",
      • "content": "( MENAFN - GlobeNewsWire - Nasdaq) The ReoPro (Abciximab) market report offers comprehensive analysis, covering market size, growth potential, and segmentation by region and country. Key drivers include the rising prevalence of coronary artery disease, the aging population, and increasing healthcare spending. North America leads, while Asia-Pacific is the fastest-growing region. The competitive landscape features Janssen Pharmaceuticals, with major trends focusing on automation, personalized medicine, and advanced therapeutic integration. Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"ReoPro (Abciximab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts\" has been added to ResearchAndMarkets.com's offering. The ReoPro (Abciximab) market report offers a comprehensive analysis of the market's core attributes, highlighting factors such as market size, growth potential, and segmentation. This document provides a detailed regional breakdown, identifying key countries and assessing historical data alongside future growth forecasts. The report also delves into the competitive landscape, delivering insights into market share, emerging trends, and strategic initiatives influencing market dynamics. Historically, the market's growth has been fueled by a surge in coronary artery disease prevalence, an aging demographic, expanded healthcare infrastructure, the uptake of advanced treatments, and increased healthcare spending in emerging economies. During the forecast period, growth prospects are anticipated from broader geographical market reach, entry into related industries, enhanced service support, and increased industry integration. Key trends include the rise of automation, the use of advanced therapeutic agents, strides in genomics, biomarker identification, and the proliferation of personalized medicine. The ReoPro (Abciximab) market's expansion is closely linked to the growing prevalence of coronary artery disease (CAD). CAD, characterized by narrowed or blocked coronary arteries, elevates the risk of heart attacks. Lifestyle factors like poor diet, inactivity, smoking, obesity, and rising diabetes and hypertension rates are contributing to this trend. ReoPro (Abciximab) plays a pivotal role in CAD management by preventing blood clots during interventions such as percutaneous coronary intervention (PCI). Recent CDC data indicates coronary heart disease was the principal cause of heart-related fatalities, accounting for 371,506 deaths in 2022. With 5% of those aged 20 and older affected by CAD, the market is poised for growth. The aging population is another significant driver. This demographic shift, driven by extended life expectancy and improved healthcare, affects the market as ReoPro (Abciximab) is pivotal for elder care, reducing clotting risks during and after PCIs. Increasing numbers of the elderly-17.3% of the population in 2022, projected to rise to 22% by 2040-underscore the market's potential. Cardiovascular diseases (CVDs), including heart attacks, heart failure, strokes, and hypertension, further propel market potential, aggravated by aging populations and lifestyle choices. ReoPro (Abciximab) mitigates risks in these conditions through platelet aggregation inhibition during procedures. CDC data revealed 702,880 heart disease-related deaths in 2022, with 805,000 heart attacks occurring annually in the U.S., underscoring an urgent need for effective interventions. Janssen Pharmaceuticals (Johnson & Johnson) emerges as a key player in this market, focusing on North America, currently the largest region. However, Asia-Pacific is projected to exhibit the highest growth rates in the coming years. The report spans regions including Asia-Pacific, Western and Eastern Europe, North and South America, and the Middle East and Africa, with countries covered such as the USA, China, Japan, Germany, and Brazil, amongst others. This report provides a detailed perspective on the ReoPro (Abciximab) market, analyzing biosimilars, cardiovascular intervention devices, compounding kits, and related anticoagulants. The market encompasses factory gate values, emphasizing the manufacturer's selling prices, establishing a comprehensive industry view. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 MENAFN08052025004107003653ID1109522691 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:42",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "research",
        • "pharma and healthcare"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": true
      },
    • -
      {
      • "article_id": "dcef58611d3950cbc4df9eb80aa68e6c",
      • "title": "Tysabri (Natalizumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2034",
      • "link": "https://menafn.com/1109522692/Tysabri-Natalizumab-Market-Research-Report-2025-Epidemiology-Pipeline-Analysis-Market-Insights-Forecasts-2019-2034",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Tysabri (natalizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts\" report has ...",
      • "content": "( MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Tysabri (natalizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts\" report has been added to ResearchAndMarkets.com's offering. This Tysabri (natalizumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. Tysabri (natalizumab) is a monoclonal antibody used to treat relapsing multiple sclerosis (MS) and Crohn's disease by reducing inflammation and nerve damage. It helps decrease the frequency of relapses and slows the progression of physical disability in adults with relapsing forms of MS, including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS). The primary indications for tysabri (natalizumab) are multiple sclerosis and Crohn's disease. Multiple sclerosis is a condition that causes the breakdown of the protective covering of nerves. Tysabri is used in various patient settings, including inpatient and outpatient, and is distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies. Major players operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, and Polpharma Biologics. North America was the largest region in the tysabri (natalizumab) market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. Market growth during the historic period can be attributed to Tysabri's efficacy in treating multiple sclerosis, its ability to target specific immune cells, its approval for multiple autoimmune disorders, robust clinical trial data, rising demand for effective disease-modifying therapies, and increasing patient awareness of available treatment options. Growth during the forecast period will be driven by the increasing prevalence of autoimmune disorders, rising demand for effective treatments for multiple sclerosis and Crohn's disease, advancements in biosimilars, expanding patient access in underserved regions, and ongoing clinical research supporting its use in other autoimmune conditions. Key trends include the rising adoption of biosimilars, expanding therapeutic applications beyond multiple sclerosis, a stronger focus on personalized medicine, growing global distribution partnerships, enhanced patient access through affordability initiatives, and continued advancements in immune-modulating therapies. The growth of the tysabri (natalizumab) market is being significantly influenced by the rise in the prevalence of autoimmune disorders. Autoimmune conditions, such as multiple sclerosis and Crohn's disease, occur when the immune system attacks the body's own tissues, causing inflammation and long-term damage. This increase in autoimmune diseases is linked to genetic factors, environmental influences, and improved awareness and diagnosis, leading to more cases being identified. In March 2024, the National Health Council reported that autoimmune diseases affected approximately 50 million Americans, with the number of cases rising by 3-12% annually. Globally, multiple sclerosis cases grew by 30% in 2022 compared to the previous decade. As a result, Tysabri, which targets specific immune cells to prevent inflammation, is becoming an essential treatment for these conditions, driving market growth. The rising trend of personalized medicine is propelling the tysabri market. Personalized medicine tailors treatments based on a patient's genetic makeup, environment, and lifestyle, improving efficacy while minimizing side effects. Tysabri is an example of such treatment, particularly for relapsing forms of multiple sclerosis. It targets specific disease activities and risk profiles, ensuring more precise therapeutic outcomes. The FDA's approval of 16 novel personalized therapies in 2023 highlights the growing demand for targeted treatments, further driving the adoption of Tysabri and similar therapies. A key trend in the tysabri (natalizumab) market is the growing focus on biosimilars, which offer cost-effective alternatives to branded drugs like Tysabri. In January 2024, Sandoz launched Tyruko (natalizumab), the first biosimilar to Tysabri for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). This development not only strengthens the biosimilar portfolio but also enhances patient access to effective and affordable treatments, particularly in underserved regions. The increasing availability of biosimilars is expected to expand the market for Tysabri, improving overall disease management and patient outcomes. Key Topics Covered: 1. Executive Summary 2. Tysabri (natalizumab) Market Characteristics 3. Tysabri (natalizumab) Market Biologic Drug Characteristics 3.1. Molecule Type 3.2. Route of Administration (ROA) 3.3. Mechanism of Action (MOA) 3.4. Safety and Efficacy 4. Tysabri (natalizumab) Market Trends and Strategies 5. Tysabri (natalizumab) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market 6. Global Tysabri (natalizumab) Growth Analysis and Strategic Analysis Framework 6.1. Global Tysabri (natalizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints) 6.2. Analysis of End Use Industries 6.3. Global Tysabri (natalizumab) Market Growth Rate Analysis 6.4. Global Tysabri (natalizumab) Historic Market Size and Growth, 2019-2024, Value ($ Billion) 6.5. Global Tysabri (natalizumab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion) 6.6. Global Tysabri (natalizumab) Total Addressable Market (TAM) 7. Global Tysabri (natalizumab) Market Pricing Analysis & Forecasts 8. Tysabri (natalizumab) Market Segmentation 8.1. Global Tysabri (natalizumab) Market, Segmentation by Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Multiple Sclerosis Crohn's Disease 8.2. Global Tysabri (natalizumab) Market, Segmentation by Patient Setting, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Inpatient Outpatient 8.3. Global Tysabri (natalizumab) Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Hospital Pharmacies Retail Pharmacies Online Pharmacies 9. Global Tysabri (natalizumab) Market Epidemiology of Clinical Indications 9.1. Drug Side Effects 9.2. Incidence and Prevalence of Clinical Indications 10. Tysabri (natalizumab) Market Regional and Country Analysis 10.1. Global Tysabri (natalizumab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 10.2. Global Tysabri (natalizumab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Companies Featured Biogen Idec Inc. Sandoz International GmbH Polpharma Biologics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 MENAFN08052025004107003653ID1109522692 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:42",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "pharma and healthcare",
        • "financial markets"
        ],
      • -
        "ai_region": [
        • "dublin,texas,united states of america,north america",
        • "dublin,georgia,united states of america,north america",
        • "dublin,virginia,united states of america,north america",
        • "dublin,ohio,united states of america,north america",
        • "dublin,new hampshire,united states of america,north america",
        • "dublin,pennsylvania,united states of america,north america",
        • "dublin,california,united states of america,north america"
        ],
      • "ai_org": null,
      • "duplicate": true
      },
    • -
      {
      • "article_id": "8e17982de51f6c78a0ad92ca31fa77fe",
      • "title": "Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2034",
      • "link": "https://menafn.com/1109522688/Rituxan-Hycela-Rituxan-Mabthera-Rituximab-Market-Research-Report-2025-Epidemiology-Pipeline-Analysis-Market-Insights-Forecasts-2019-2034",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & ...",
      • "content": "( MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts\" report has been added to ResearchAndMarkets.com's offering. This Rituxan Hycela, Rituxan Mabthera (Rituximab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. Rituxan Hycela and Rituxan MabThera (rituximab) are monoclonal antibody therapies that target CD20-positive B-cells. These treatments are used for conditions such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and autoimmune diseases such as rheumatoid arthritis. Rituxan Hycela is a subcutaneous formulation, while Rituxan MabThera is administered intravenously. The main formulations of Rituxan Hycela and Rituxan MabThera (rituximab) are available in 10 ml and 50 ml vials. The 10 ml vial of Rituxan Hycela is intended for patients who require a smaller dose of the medication, often suitable for those beginning treatment or needing lower dosages, allowing for personalized care. The medication is administered through subcutaneous, intravenous, and parenteral routes and is distributed through hospital pharmacies, online pharmacies, and other channels. It is used in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other conditions. The key companies operating in the rituxan hycela, rituxan mabthera (rituximab) market is F. Hoffmann-La Roche AG (Genentech Inc.) North America was the largest region in the rituxan hycela, rituxan mabthera (rituximab) market in 2024. The regions covered in rituxan hycela and rituxan mabthera (rituximab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the rituxan hycela and rituxan mabthera (rituximab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Market growth during the historic period can be attributed to the rising prevalence of autoimmune diseases, the increasing incidence of non-Hodgkin's lymphoma, the growing adoption of biologics, favorable reimbursement policies, and improving healthcare infrastructure. Growth during the market's forecast period can be attributed to the rising geriatric population, increasing patient awareness, growth in emerging markets, supportive government policies, and the growing demand for targeted therapies. Key trends during this period include a shift towards subcutaneous formulations, increased competition from biosimilars, strategic collaborations among market players, a focus on patient-centric treatment options, and geographic expansion into developing regions. The increasing prevalence of autoimmune diseases is expected to drive the growth of the Rituxan Hycela and Rituxan MabThera (rituximab) market. Autoimmune diseases occur when the immune system mistakenly attacks the body's own cells, tissues, or organs, leading to inflammation and potential damage. The rise in these conditions is linked to factors such as genetic predisposition, environmental factors, infections, and lifestyle changes that impact the immune system. Rituximab helps manage autoimmune diseases by targeting and depleting specific immune cells (B-cells) that mistakenly attack healthy tissues. For example, in October 2023, a report from the National Health Service England highlighted the ongoing rise in the prevalence of diabetes. In England, the number of people with type 1 diabetes increased to 270,935 between 2021 and 2022. This rising incidence of autoimmune diseases is a key factor driving the market for Rituxan Hycela and Rituxan MabThera (rituximab). The growing healthcare expenditure is another factor expected to propel the growth of the Rituxan Hycela and Rituxan MabThera (rituximab) market. Healthcare expenditure encompasses all spending on healthcare goods and services, including personal health care, preventive services, and public health activities, which aim to improve health outcomes. This expenditure is increasing due to factors such as an aging population, the rise of chronic diseases, advancements in medical technology, high drug prices, and increased demand for healthcare services. Higher healthcare spending improves access to advanced treatments such as Rituxan Hycela and Rituxan MabThera, boosting demand for effective therapies in the treatment of oncology and autoimmune diseases. For instance, in May 2024, a report from the Office for National Statistics noted that healthcare expenditure in the UK rose by 5.6% from 2022 to 2023, compared to a slower growth rate of 0.9% in 2022. Long-term health and social care expenditure also saw an increase of 2.8% in real terms in 2022. The rise in healthcare spending is contributing to the growth of the Rituxan Hycela and Rituxan MabThera market. A significant trend in the Rituxan Hycela and Rituxan MabThera (rituximab) market is the development of biosimilar anti-CD20 monoclonal antibodies, which offer cost-effective alternatives and improve patient access to treatment. Biosimilars are biologic drugs highly similar to reference products such as Rituxan, designed to target CD20 on B-cells and provide a more affordable treatment option. RIABNI is a biosimilar version of Rituxan, containing the same amino acid sequence and available in the same dosage form, strength, and administration route. The development of such biosimilars is expected to further drive the market for Rituxan Hycela and Rituxan MabThera. Key Topics Covered: 1. Executive Summary 2. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Characteristics 3. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Biologic Drug Characteristics 3.1. Molecule Type 3.2. Route of Administration (ROA) 3.3. Mechanism of Action (MOA) 3.4. Safety and Efficacy 4. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Trends and Strategies 5. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market 6. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Growth Analysis and Strategic Analysis Framework 6.1. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints) 6.2. Analysis of End Use Industries 6.3. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Growth Rate Analysis 6.4. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Historic Market Size and Growth, 2019-2024, Value ($ Million) 6.5. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Million) 6.6. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Total Addressable Market (TAM) 7. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Pricing Analysis & Forecasts 8. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Segmentation 8.1. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million 10ml 50ml 8.2. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation by Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Subcutaneous Intravenous Parenteral 8.3. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Hospital Pharmacy Online Pharmacy Others Distribution Channel 8.4. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia Rheumatoid Arthritis Other Applications 9. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Epidemiology of Clinical Indications 9.1. Drug Side Effects 9.2. Incidence and Prevalence of Clinical Indications 10. Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Regional and Country Analysis 10.1. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million 10.2. Global Rituxan Hycela, Rituxan Mabthera (Rituximab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 MENAFN08052025004107003653ID1109522688 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:20",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "research"
        ],
      • -
        "ai_region": [
        • "dublin,texas,united states of america,north america",
        • "dublin,georgia,united states of america,north america",
        • "dublin,virginia,united states of america,north america",
        • "dublin,ohio,united states of america,north america",
        • "dublin,new hampshire,united states of america,north america",
        • "dublin,pennsylvania,united states of america,north america",
        • "dublin,california,united states of america,north america"
        ],
      • -
        "ai_org": [
        • "rituximab",
        • "rituxan mabthera",
        • "rituxan hycela"
        ],
      • "duplicate": true
      },
    • -
      {
      • "article_id": "981dcc756747663a9e382df759ae2cc7",
      • "title": "How To Maximise The IP In Your Business: Building And Managing A Patent Portfolio To Best Support Your Business Training Course (ONLINE EVENT: July 3, 2025)",
      • "link": "https://menafn.com/1109522682/How-To-Maximise-The-IP-In-Your-Business-Building-And-Managing-A-Patent-Portfolio-To-Best-Support-Your-Business-Training-Course-ONLINE-EVENT-July-3-2025",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - GlobeNewsWire - Nasdaq) Expert trainers will explain how to meet the challenges of an extensive patent filing programme and how to manage the costs effectively, in order to achieve maximum ...",
      • "content": "( MENAFN - GlobeNewsWire - Nasdaq) Expert trainers will explain how to meet the challenges of an extensive patent filing programme and how to manage the costs effectively, in order to achieve maximum coverage on minimum budget. Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Building and Managing a Patent Portfolio to Best Support your Business Training Course\" training has been added to ResearchAndMarkets.com's offering. This comprehensive one-day course will take you through the IP commercialisation process and explain how to maximise the IP in your business. The expert trainers will explain how to meet the challenges of an extensive patent filing programme and how to manage the costs effectively, in order to achieve maximum coverage on minimum budget. This practical and intense one-day course will take you through preparing a patent portfolio for multinational litigation and managing a portfolio with a view to detecting infringement. Using their extensive knowledge and industry experience the trainers will provide you with strategies to exploit your portfolio, maximising it's full potential. Key topics included in this course include: Working as a multinational team to file and prosecute patent application Meeting the challenges of an extensive patent filing programme Managing a cost-effective patent filing programme Achieving maximum coverage on minimum budget Preparing a patent portfolio for multinational litigation Managing a patent portfolio with a view to detecting infringement Strategies to exploit your patent portfolio Maximising your patent portfolio Benefits of attending Gain practical tips enabling you to build a successful patent portfolio Understand the multinational aspects of developing and maintaining a patent portfolio Gain an insight into how other businesses are addressing the issues and pressures facing them Learn ways to maximise your growing portfolio Hear top rated speakers outlining the issues and pressures facing industry today Identify techniques to overcome the issues surrounding managing an existing portfolio You will also have the opportunity to network with peers facing the same challenges as you in managing or advising on a patent portfolio. Certifications: CPD: 6 hours for your records Certificate of completion Who Should Attend: In-house patent lawyers/agents Private practice patent lawyers/agents IP lawyers and legal advisors Senior patent administrators and paralegals Others responsible for managing a patent portfolio Key Topics Covered: What is a patent portfolio good for? Patent protection - general aspects Translating innovation into inventions Translating inventions into patent applications Creation of a patent portfolio Maintenance of a patent portfolio Internal processes and governance Budgeting IP stagegate/agile models Invention disclosure forms Patent Committees (who has the authority?) Inventors rewards and recognition programmes Meeting the challenges of an extensive filing programme - Part 1 Managing the drafting process Patent filing strategy Selecting territorial coverage Managing and understanding patent portfolio information Coordinating prosecution of a patent family Meeting the challenges of an extensive filing programme - Part 2 Growing a patent portfolio - generation of inventions The transition from start-up to multinational Outsourcing strategies - what to keep internal / what to externalize Working effectively with patent agents and agents' selection Monitoring patent agents' performance Achieving maximum coverage on minimum budget Matching patent filing with commercial strategy Treatment of higher and lower priority cases Keeping your patent portfolio fresh External collaborations: How to split the patent rights? Ensuring quality of a patent portfolio Analysing for quality Patent portfolio pruning Communicating internally about patents Preparing a patent portfolio for multinational litigation Drafting patent applications with litigation considerations in mind Identifying territories for your patent filing programme Co-ordinating prosecution of patent families across jurisdictions Liaison between prosecutor and litigator The prospects of settlement Managing a portfolio with a view to detecting infringement Reviewing your patent portfolio Watching your competitors Infringement hunting Strategies to exploit your portfolio - extracting value from your patent portfolio Connections between patent portfolio management and value extraction Processes for optimising value extraction, mapping, ranking systems, claim charting Patent licensing and enforcement Maximising your patent portfolio - when dreams and budgets collide Key takeaways Discussion and final questions For more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 MENAFN08052025004107003653ID1109522682 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:20",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "positive",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "startups & entrepreneurship"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": true
      },
    • -
      {
      • "article_id": "95185a772224006076171941b0180b18",
      • "title": "Rett Syndrome Pipeline Analysis Report 2025: Comprehensive Insights Into 20+ Companies, 20+ Pipeline Drugs And The Therapeutics Landscape",
      • "link": "https://menafn.com/1109522685/Rett-Syndrome-Pipeline-Analysis-Report-2025-Comprehensive-Insights-Into-20-Companies-20-Pipeline-Drugs-And-The-Therapeutics-Landscape",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Rett Syndrome - Pipeline Insight, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.This ...",
      • "content": "( MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Rett Syndrome - Pipeline Insight, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Rett Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Rett Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Rett Syndrome. Rett Syndrome Emerging Drugs Chapters This segment of the Rett Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Rett Syndrome Emerging Drugs Blarcamesine: Anavex Life Sciences Corp Blarcamesine is a small molecule, orally administered drug that restores cellular homeostasis by targeting SIMGAR1 and muscarinic receptors that is pivotal to restoring cellular homeostasis and promoting neuroplasticity. The drug candidate has received Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA. Currently, the drug is in Phase III stage of its development for the treatment of Rett syndrome. TSHA-102: Taysha GTx TSHA-102 is a self-complementary intrathecal delivered AAV9 gene transfer therapy in clinical evaluation. TSHA-102 is constructed from a neuronal specific promoter, MECP2, a gene essential for neuronal and synaptic function in the brain. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) platform designed to regulate cellular MECP2 expression. TSHA-102 has received Orphan Drug and Rare Pediatric Disease designations from the United States (U.S.) Food and Drug Administration (FDA) and has been granted Orphan Drug designation from the European Commission. Currently, the drug is in Phase I/II stage of its development for the treatment of Rett syndrome. NGN-401: Neurogene NGN-401 is an investigational AAV9 gene therapy being developed as a one line treatment for Rett syndrome. It is the first clinical candidate to deliver the full-length human MECP2 gene under the control of Neurogene's EXACT technology. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with Rett Syndrome. Rett Syndrome: Therapeutic Assessment This segment of the report provides insights about the different Rett Syndrome drugs segregated based on following parameters that define the scope of the report, such as: Major Players in Rett Syndrome There are approx. 12+ key companies which are developing the therapies for Rett Syndrome. The companies which have their Rett Syndrome drug candidates in the most advanced stage, i.e. phase III include, Anavex Life Sciences Corp. Phases The report covers around 15+ products under different phases of clinical development like: Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Rett Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as: Oral Intravenous Subcutaneous Parenteral Topical Molecule Type Products have been categorized under various Molecule types such as: Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Product Type Drugs have been categorized under various product types like Mono, Combination and Mono/Combination. Pipeline Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rett Syndrome therapeutic drugs key players involved in developing key drugs. Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rett Syndrome drugs. Key Questions Current Treatment Scenario and Emerging Therapies: How many companies are developing Rett Syndrome drugs? How many Rett Syndrome drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rett Syndrome? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rett Syndrome therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Rett Syndrome and their status? What are the key designations that have been granted to the emerging drugs? Key Topics Covered Introduction Executive Summary Rett Syndrome: Overview Causes Pathophysiology Signs and Symptoms Diagnosis Disease Management Pipeline Therapeutics Comparative Analysis Therapeutic Assessment Assessment by Product Type Assessment by Stage and Product Type Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Rett Syndrome - The Publisher's Analytical Perspective Late Stage Products (Phase III) Comparative Analysis Blarcamesine: Anavex Life Sciences Corp Product Description Research and Development Product Development Activities Mid Stage Products (Phase II) Comparative Analysis Drug Name: Company Name Product Description Research and Development Product Development Activities Early Stage Products (Phase I/II) Comparative Analysis TSHA-102: Taysha GTx Product Description Research and Development Product Development Activities Preclinical and Discovery Stage Products Comparative Analysis Drug Name: Company Name Product Description Research and Development Product Development Activities Inactive Products Comparative Analysis Rett Syndrome Key Companies Rett Syndrome Key Products Rett Syndrome - Unmet Needs Rett Syndrome - Market Drivers and Barriers Rett Syndrome - Future Perspectives and Conclusion Rett Syndrome Analyst Views Rett Syndrome Key Companies For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 MENAFN08052025004107003653ID1109522685 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:20",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "pharma and healthcare"
        ],
      • -
        "ai_region": [
        • "dublin,texas,united states of america,north america",
        • "dublin,georgia,united states of america,north america",
        • "dublin,virginia,united states of america,north america",
        • "dublin,ohio,united states of america,north america",
        • "dublin,new hampshire,united states of america,north america",
        • "dublin,pennsylvania,united states of america,north america",
        • "dublin,california,united states of america,north america"
        ],
      • -
        "ai_org": [
        • "rett syndrome pipeline"
        ],
      • "duplicate": true
      },
    • -
      {},
    • -
      {
      • "article_id": "3dc0fc514991b2ca3e9f0c5942df5a9c",
      • "title": "Anti-Cancer Mabs Market Research Report 2025: Rising Cancer Incidence Spurs Demand For Targeted Anti-Cancer Mabs Treatments - Historic Trends And Forecasts, 2019-2024, 2024-2029F, 2034F",
      • "link": "https://menafn.com/1109522689/Anti-Cancer-Mabs-Market-Research-Report-2025-Rising-Cancer-Incidence-Spurs-Demand-For-Targeted-Anti-Cancer-Mabs-Treatments-Historic-Trends-And-Forecasts-2019-2024-2024-2029F-2034F",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - GlobeNewsWire - Nasdaq) Explore the thriving Anti-Cancer mAbS market with rapid growth from $69.33B in 2024 to $109.88B by 2029 (CAGR 9.3%). Key drivers include rising cancer rates and ...",
      • "content": "( MENAFN - GlobeNewsWire - Nasdaq) Explore the thriving Anti-Cancer mAbS market with rapid growth from $69.33B in 2024 to $109.88B by 2029 (CAGR 9.3%). Key drivers include rising cancer rates and innovations in drug delivery and AI. Leading companies are making strategic moves through clinical trials and partnerships. North America is currently dominant, with Asia Pacific set for rapid expansion. This report details size, growth, trends, and strategies crucial for success. Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Anti-Cancer MAbS Market Report 2025\" has been added to ResearchAndMarkets.com's offering. The anti-cancer monoclonal antibodies (mAbs) market is experiencing substantial growth, driven by increasing cancer incidence and demand for effective treatments. The market is projected to expand from $69.33 billion in 2024 to $109.88 billion by 2029, with a CAGR of 9.3%. Advancements in immunotherapy, the adoption of combination therapies, and innovative drug delivery technologies are significant contributors to this growth. Regionally, North America dominated the market in 2023, while Asia Pacific is set to be the fastest-growing region over the coming years. The market encompasses a wide array of mAbs such as avastin, Herceptin, and keytruda, valued at factory gate levels, covering the industrial transactions between manufacturers and subsequent business customers, not resale values further down the supply chain. Growth is propelled by the increasing prevalence of cancer, as evidenced by PubMed's 2022 report predicting 1.9 million new global cancer cases. With cancer affecting millions globally, targeted therapies like anticancer mAbs are in heightened demand. Furthermore, the escalation in clinical trials underpins market expansion, with noting a sharp rise in registered trials from 365,000 in 2021 to 452,604 in 2023. Industry players, including Y-mAbs Therapeutics Inc., are pioneering advances with clinical trials, such as the Phase I trial for GD2-Targeted Radioimmunotherapy. This trial evaluates the GD2-SADA therapy's potential in treating solid tumors like small cell lung cancer, harnessing a two-step radiation delivery method aimed at minimizing damage to healthy tissues. Innovation remains critical, typified by Roche Holding AG's 2022 launch of PHESGO, a combination treatment for HER2-positive breast cancer. PHESGO offers subcutaneous administration, a patient-friendly alternative to intravenous delivery, illustrating the industry's shift towards more convenient therapeutic options. The competitive landscape features major corporations like Amgen Inc., Merck & Co., Inc., and Roche, engaging in strategic partnerships and innovation to maintain market leadership. For instance, Merck's acquisition of Prometheus Biosciences Inc. for $10.8 billion enhances its immunology portfolio with the addition of PRA023, now termed MK-7240, focused on addressing autoimmune disorders. The anticancer mAbs market report provides a thorough overview of the sector, including market size, regional shares, and detailed segmentation. It highlights key players like Eli Lilly and Company, Bristol Myers Squibb, and Pfizer Inc., alongside the impact of biotechnology advances and artificial intelligence integration in drug discovery, pivotal in strengthening the market's trajectory. This comprehensive assessment signifies the market's dynamic nature and the myriad opportunities within, shaped by innovation, strategic alliances, and a growing need for effective cancer therapies across the globe. Key Attributes: Report Attribute Details No. of Pages 175 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $76.92 Billion Forecasted Market Value (USD) by 2029 $109.88 Billion Compound Annual Growth Rate 9.3% Regions Covered Global Key Topics Covered: 1. Executive Summary 2. Anti-Cancer MAbS Market Characteristics 3. Anti-Cancer MAbS Market Trends and Strategies 4. Anti-Cancer MAbS Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market 5. Global Anti-Cancer MAbS Growth Analysis and Strategic Analysis Framework 5.1. Global Anti-Cancer MAbS PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints) 5.2. Analysis of End Use Industries 5.3. Global Anti-Cancer MAbS Market Growth Rate Analysis 5.4. Global Anti-Cancer MAbS Historic Market Size and Growth, 2019-2024, Value ($ Billion) 5.5. Global Anti-Cancer MAbS Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion) 5.6. Global Anti-Cancer MAbS Total Addressable Market (TAM) 6. Anti-Cancer MAbS Market Segmentation 6.1. Global Anti-Cancer MAbS Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 6.2. Global Anti-Cancer MAbS Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 6.3. Global Anti-Cancer MAbS Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 7. Anti-Cancer MAbS Market Regional and Country Analysis 7.1. Global Anti-Cancer MAbS Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 7.2. Global Anti-Cancer MAbS Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Companies Featured Amgen Inc. Bristol Myers Squibb Company Eli Lilly and Company F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc Johnson & Johnson Novartis AG Merck & Co. Inc. Spectrum Pharmaceuticals Inc. AstraZeneca plc. Pfizer Inc. Gilead Sciences Inc. Bayer HealthCare ImmunoGen Inc. Genentech Inc. AbbVie Inc. Takeda Pharmaceuticals Seattle Genetics Regeneron Pharmaceuticals Celgene Ipsen Daiichi Sankyo Kite Pharma ADC Therapeutics MacroGenics Inc. BioXcel Therapeutics Zymeworks Inc. Exelixis Inc. Blueprint Medicines Erytech Pharma Oncopeptides AB For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Anti-Cancer MAbS Market CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 MENAFN08052025004107003653ID1109522689 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:20",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "pharma and healthcare",
        • "diseases"
        ],
      • "ai_region": null,
      • "ai_org": null,
      • "duplicate": true
      },
    • -
      {
      • "article_id": "d8600973f5224d4b8a4c86b90f364734",
      • "title": "Artificial Intelligence (AI) And The Metaverse Overview And IP Perspective Training Course (ONLINE EVENT: July 17, 2025)",
      • "link": "https://menafn.com/1109522683/Artificial-Intelligence-AI-And-The-Metaverse-Overview-And-IP-Perspective-Training-Course-ONLINE-EVENT-July-17-2025",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Artificial Intelligence (AI) and The Metaverse - An Overview and IP Perspective\" conference has been added to ...",
      • "content": "( MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Artificial Intelligence (AI) and The Metaverse - An Overview and IP Perspective\" conference has been added to ResearchAndMarkets.com's offering. This course will ensure you are informed about the latest technological developments in AI and the Metaverse and how they work - which is an essential prerequisite to understanding the intellectual property issues that arise from their use - all of which this course covers. This far into the 21st century, everyone should be familiar with the concepts of artificial intelligence and the metaverse. This course not only explains what these are but also explains the intellectual property issues that arise from using them and the areas you need to know to operate in today's (and tomorrow's) world! The first half of this 3-hour programme is an explanation of AI and the metaverse and the IP and other legal issues arising from them; the second half is a workshop, working through a practical scenario where you will negotiate an IP clause from a fact pattern involving these issues. Attending this event also gives you the opportunity to ask questions of the expert presenter. Benefits of attending Understand the latest developments in AI and the Metaverse Get to grips with the intellectual property issues that arise from their use Learn about the implications of using AI-generated content Get up to date with the latest UK and EU AI legislation, regulation and case law Consider the commercialisation of the Metaverse for your business Certifications: CPD : 3 hours for your records Certificate of completion Who Should Attend: In-house lawyers Private practice lawyers Patent, IP, trademarks or licensing counsel Business development managers Commercial managers and business executives Compliance officers Board directors Agenda Artificial Intelligence (AI) What is AI? AI engines How does AI work - types How does AI work - techniques AI technology International debate Legal implications of using AI to generate content IP protection of AI-generated content Patent example Copyright example AI and copyright Using other's IP to generate AI-generated content Using AI to generate content Practical tips - what to do Concerns UK AI legislation, regulation and case law EU AI legislation and regulation Legal issues in AI projects The Metaverse The Metaverse - evolution What is the metaverse? Commercialisation of the metaverse Metaverse issues and possible solutions Trade mark issues in the metaverse Copyright issues in the metaverse Patent issues in the metaverse Other issues in the metaverse Workshop: Use of AI and issues with IP rights flowing from this A practical session negotiating an IP clause Final questions For more information about this conference visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 MENAFN08052025004107003653ID1109522683 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:20",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "artificial intelligence"
        ],
      • -
        "ai_region": [
        • "dublin,ohio,united states of america,north america",
        • "dublin,virginia,united states of america,north america",
        • "dublin,california,united states of america,north america",
        • "dublin,new hampshire,united states of america,north america",
        • "dublin,pennsylvania,united states of america,north america",
        • "dublin,texas,united states of america,north america",
        • "dublin,georgia,united states of america,north america"
        ],
      • "ai_org": null,
      • "duplicate": true
      },
    • -
      {
      • "article_id": "c23fb4ac59590238f3b06247f45908e5",
      • "title": "Autism Commercial And Clinical Assessment Report 2025: Insights Into The Pipeline, Drugs, Companies, And Unmet Needs",
      • "link": "https://menafn.com/1109522686/Autism-Commercial-And-Clinical-Assessment-Report-2025-Insights-Into-The-Pipeline-Drugs-Companies-And-Unmet-Needs",
      • "keywords": null,
      • -
        "creator": [
        • "marketing@menafn.com (MENAFN)"
        ],
      • "description": "(MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Autism - Pipeline Insight, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.This report ...",
      • "content": "( MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The \"Autism - Pipeline Insight, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering. This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Autism market. A detailed picture of the Autism pipeline landscape is provided, which includes the disease overview and Autism treatment guidelines. The assessment part of the report embraces in-depth Autism commercial assessment and clinical assessment of the Autism pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autism collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details. Autism of Pipeline Development Activities The report provides insights into: All of the companies that are developing therapies for the treatment of Autism with aggregate therapies developed by each company for the same. Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Autism treatment. Autism key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Autism market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc. Report Highlights A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Autism. In the coming years, the Autism market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies and academics that are working to assess challenges and seek opportunities that could influence Autism R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. A detailed portfolio of major pharma players who are involved in fueling the Autism treatment market. Several potential therapies for Autism are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Autism market size in the coming years. This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Autism) includes therapeutic assessment and comparative analysis. This will support clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. Key Questions Answered What are the current options for Autism treatment? How many companies are developing therapies for the treatment of Autism? What are the principal therapies developed by these companies in the industry? How many therapies are developed by each company for the treatment of Autism? How many Autism emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Autism? Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Autism market? Which are the dormant and discontinued products and the reasons for the same? What is the unmet need for current therapies for the treatment of Autism? What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Autism therapies? What are the clinical studies going on for Autism and their status? What are the results of the clinical studies and their safety and efficacy? What are the key designations that have been granted for the emerging therapies for Autism? How many patents are granted and pending for the emerging therapies for the treatment of Autism? Key Topics Covered 1. Report Introduction 2. Autism 2.1. Overview 2.2. History 2.3. Autism Symptoms 2.4. Causes 2.5. Pathophysiology 2.6. Autism Diagnosis 2.6.1. Diagnostic Guidelines 3. Autism Current Treatment Patterns 3.1. Autism Treatment Guidelines 4. Autism - The Publisher's Analytical Perspective 4.1. In-depth Commercial Assessment 4.1.1. Autism companies collaborations, Licensing, Acquisition -Deal Value Trends 4.1.1.1. Assessment Summary 4.1.2. Autism Collaboration Deals 4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis 4.1.2.2. Company-University Collaborations (Licensing/Partnering) Analysis 4.1.2.3. Autism Acquisition Analysis 5. Therapeutic Assessment 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development 5.1.2. Assessment by Product Type (Mono/Combination) 5.1.2.1. Assessment by Stage and Product Type 5.1.3. Assessment by Route of Administration 5.1.3.1. Assessment by Stage and Route of Administration 5.1.4. Assessment by Molecule Type 5.1.4.1. Assessment by Stage and Molecule Type 5.1.5. Assessment by MOA 5.1.5.1. Assessment by Stage and MOA 5.1.6. Assessment by Target 5.1.6.1. Assessment by Stage and Target 6. Autism Late Stage Products (Phase-III) 7. Autism Mid Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10. Inactive Products 11. Dormant Products 12. Autism Discontinued Products 13. Autism Product Profiles 13.1. Drug Name: Company 13.1.1. Product Description 13.1.1.1. Product Overview 13.1.1.2. Mechanism of action 13.1.2. Research and Development 13.1.2.1. Clinical Studies 13.1.3. Product Development Activities 13.1.3.1. Collaboration 13.1.3.2. Agreements 13.1.3.3. Acquisition 13.1.3.4. Patent Detail 13.1.4. Tabulated Product Summary 13.1.4.1. General Description Table 14. Autism Key Companies 15. Autism Key Products 16. Dormant and Discontinued Products 16.1. Dormant Products 16.1.1. Reasons for being dormant 16.2. Discontinued Products 16.2.1. Reasons for the discontinuation 17. Autism Unmet Needs 18. Autism Future Perspectives 19. Autism Analyst Review 20. Appendix 21. Report Methodology 21.1. Secondary Research 21.2. Expert Panel Validation For more information about this clinical trials report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 MENAFN08052025004107003653ID1109522686 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.",
      • "pubDate": "2025-05-08 04:31:20",
      • "pubDateTZ": "UTC",
      • "image_url": "https://menafn.com/includes/img/logo.jpg",
      • "video_url": null,
      • "source_id": "menafn",
      • "source_name": "Menafn",
      • "source_priority": 1117534,
      • "source_url": "https://menafn.com",
      • "source_icon": "https://i.bytvi.com/domain_icons/menafn.png",
      • "language": "english",
      • -
        "country": [
        • "honduras",
        • "united states of america",
        • "el salvador",
        • "jamaica",
        • "canada",
        • "haiti",
        • "barbados",
        • "mexico",
        • "argentina",
        • "netherland",
        • "cayman islands",
        • "nicaragua",
        • "colombia",
        • "brazil",
        • "cuba",
        • "bahamas",
        • "belize",
        • "grenada",
        • "venezuela",
        • "peru",
        • "guyana",
        • "suriname",
        • "chile",
        • "ecuador",
        • "puerto rico",
        • "dominican republic",
        • "costa rica",
        • "bolivia",
        • "paraguay",
        • "panama",
        • "guatemala",
        • "uruguay"
        ],
      • -
        "category": [
        • "top"
        ],
      • "sentiment": "neutral",
      • -
        "sentiment_stats": {},
      • -
        "ai_tag": [
        • "pharma and healthcare"
        ],
      • -
        "ai_region": [
        • "dublin,texas,united states of america,north america",
        • "dublin,georgia,united states of america,north america",
        • "dublin,virginia,united states of america,north america",
        • "dublin,ohio,united states of america,north america",
        • "dublin,new hampshire,united states of america,north america",
        • "dublin,pennsylvania,united states of america,north america",
        • "dublin,california,united states of america,north america"
        ],
      • "ai_org": null,
      • "duplicate": true
      }
    ],
  • "nextPage": "1746678680355349640"
}

Sub-Categories

top sports technology business science entertainment health world politics environment food